Schlagwort: Medizin

CURECA™, das vollständig automatisierte Diagnosesystem, das den zukünftigen Standard in der Diagnostik setzen wird, wird vom 28. bis 31. Juli ...

%3Cp%3EDie%20Pharmaindustrie%20in%20Deutschland%20%C3%A4u%C3%9Fert%20Besorgnis%20%C3%BCber%20das%20k%C3%BCrzlich%20vereinbarte%20Handelsabkommen%20zwischen%20der%20EU%20und%20den%20USA.%20Obwohl%20Ursula%20von%20der%20Leyen%2C%20die%20Pr%C3%A4sidentin%20der%20EU-Kommission%2C%20die%20%22Stabilit%C3%A4t%20und%20Planbarkeit%22%20des%20Abkommens%20hervorhebt%2C%20sieht%20der%20Verband%20darin%20vor%20allem%20neue%20Herausforderungen%20f%C3%BCr%20die%20globale%20Gesundheitsversorgung%20sowie%20ein%20strukturelles%20Risiko%20f%C3%BCr%20die%20pharmazeutische%20Branche.%20Seit%20den%201990er%20Jahren%20war%20der%20zollfreie%20Austausch%20von%20Medikamenten%20eine%20wesentliche%20Grundlage%20f%C3%BCr%20eine%20zuverl%C3%A4ssige%20Versorgung%20und%20die%20enge%20transatlantische%20Zusammenarbeit%20zwischen%20Europa%20und%20den%20USA%20%E2%80%93%20doch%20dieses%20Fundament%20steht%20nun%20auf%20der%20Kippe.%3C/p%3E%0A%0A%3Cp%3E%E2%80%9EWas%20f%C3%BCr%20viele%20Sektoren%20Planbarkeit%20bedeutet%2C%20stellt%20im%20Arzneimittelbereich%20eine%20strategische%20Belastung%20f%C3%BCr%20europ%C3%A4ische%20Hersteller%20dar%E2%80%9C%2C%20erkl%C3%A4rt%20Dorothee%20Brakmann%2C%20Gesch%C3%A4ftsf%C3%BChrerin%20von%20Pharma%20Deutschland.%20%E2%80%9EDer%20bisher%20geltende%20Nullzollpakt%20hat%20unsere%20Wettbewerbs-%20und%20Innovationsf%C3%A4higkeit%20gest%C3%A4rkt%20im%20Sinne%20einer%20nachhaltigen%20Arzneimittelstrategie%20in%20Europa%2C%20die%20auch%20in%20Krisenzeiten%20auf%20eigene%20Produktionsstandorte%20setzt.%E2%80%9C%20%3C/p%3E%0A%0A%3Cp%3ELaut%20Angaben%20der%20EU-Kommission%20sind%20bestimmte%20Generika%20sowie%20Rohstoffe%20von%20den%20neuen%20Z%C3%B6llen%20ausgenommen%20%E2%80%93%20dies%20wird%20als%20grunds%C3%A4tzlich%20positives%20Signal%20gewertet.%20Dennoch%20bem%C3%A4ngelt%20Brakmann%20das%20Fehlen%20klarer%20Kriterien%20und%20umfassender%20Transparenz%20zu%20diesen%20Ausnahmen.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EVerpasste%20Gelegenheit%3A%20Nullzoll%20als%20Stabilit%C3%A4tsgarant%3C/b%3E%3C/p%3E%0A%0A%3Cp%3ENoch%20im%20Jahr%202023%20hatte%20sich%20die%20EU%20innerhalb%20der%20WTO%20deutlich%20f%C3%BCr%20den%20Erhalt%20des%20zollfreien%20Handels%20mit%20Arzneimitteln%20ausgesprochen%20%E2%80%93%20als%20%E2%80%9Eglobales%20%C3%B6ffentliches%20Gut%E2%80%9C.%20Mit%20dem%20aktuellen%20Kurswechsel%20wird%20dieser%20Grundsatz%20jedoch%20faktisch%20aufgegeben.%20%E2%80%9EEin%20echter%20Fortschritt%20w%C3%A4re%20gewesen%2C%20Medikamente%20generell%20von%20Z%C3%B6llen%20auszunehmen%20%E2%80%93%20%C3%A4hnlich%20wie%20bei%20strategischen%20G%C3%BCtern%20wie%20Flugzeugen%20oder%20deren%20Teilen%E2%80%9C%2C%20betont%20Brakmann%20weiter.%20%E2%80%9EDas%20h%C3%A4tte%20echte%20Stabilit%C3%A4t%20hinsichtlich%20globaler%20Versorgungsfragen%20geschaffen.%E2%80%9C%20%3C/p%3E%0A%0A%3Cp%3EPharma%20Deutschland%20fordert%20sowohl%20die%20Bundesregierung%20als%20auch%20die%20EU-Kommission%20dazu%20auf%2C%20umgehend%20konkrete%20Auswirkungen%20auf%20die%20pharmazeutische%20Industrie%20zu%20erkennen%20und%20gezielte%20Ausgleichsma%C3%9Fnahmen%20einzuleiten%3B%20beispielsweise%20durch%20weitere%20Ausnahmen.%20Die%20Produktion%20in%20Europa%20muss%20gef%C3%B6rdert%20werden%3B%20zudem%20sollten%20gezielte%20Investitionsanreize%20geschaffen%20werden%20sowie%20eine%20Handelspolitik%20entwickelt%20werden%2C%20welche%20sowohl%20Versorgungssicherheit%20als%20auch%20Wettbewerbsf%C3%A4higkeit%20des%20Standortes%20gew%C3%A4hrleistet.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3E%3Ci%3EDer%20Verband%20Pharma%20Deutschland%20e.V.%20ist%20mitgliederst%C3%A4rkster%20Branchenverband%20innerhalb%20Deutschlands%20pharmazeutischer%20Unternehmen.%20Er%20vertritt%20rund%20400%20Mitgliedsfirmen%2C%20welche%20etwa%2080.000%20Mitarbeiterinnen%20und%20Mitarbeiter%20besch%C3%A4ftigen.%20Die%20unter%20dem%20Dach%20von%20Pharma%20Deutschland%20e.V.%20organisierten%20Unternehmen%20tragen%20entscheidend%20zur%20Sicherstellung%20einer%20zuverl%C3%A4ssigen%20Arzneimittelversorgung%20in%20Deutschland%20bei%3A%20Sie%20stellen%20nahezu%2080%20Prozent%20aller%20rezeptfreien%20Medikamente%20sowie%20fast%20zwei%20Drittel%20aller%20verschreibungspflichtigen%20Arzneien%20bereit%20-%20ebenso%20einen%20gro%C3%9Fen%20Teil%20stofflicher%20Medizinprodukte%20f%C3%BCr%20Patientinnen%20und%20Patienten.%3Cbr%20/%3E%20Weitere%20Informationen%20finden%20Sie%20unter%20www.pharmadeutschland.de.%3C/i%3E%3C/b%3E%3C/p%3E%0A%0A%3Cp%3EPressekontakt%3A%3C/p%3E%0A%3Cp%3EIhre%20Ansprechpartnerin%20in%20der%20Pressestelle%20von%20Pharma%20Deutschland%3A%3Cbr%20/%3E%3Cbr%20/%3EHannes%20H%C3%B6nemann%3Cbr%20/%3ELeiter%20Presse-%20%26%20%C3%96ffentlichkeitsarbeit%3Cbr%20/%3ET.%3A%20%2B49%20171%205618203%3Cbr%20/%3Ehoenemann%40pharmadeutschland.de%3Cbr%20/%3E%3Cbr%20/%3EAnna%20Frederike%20Gutzeit%3Cbr%20/%3ECvD%20Presse-%20%26%20%C3%96ffentlichkeitsarbeit%3Cbr%20/%3ET.%3A%20%2B49%20170%204548014%3Cbr%20/%3Egutzeit%40pharmadeutschland.de%3Cbr%20/%3E%3Cbr%20/%3E%0AGesch%C3%A4ftsstelle%20Berlin%3A%3Cbr%20/%3E%0APharma%20Deutschland%20e.V.%3Cbr%20/%3E%0AFriedrichstra%C3%9Fe%20134%2C%3Cbr%20/%3E%0A10117%20Berlin%2C%3Cbr%20/%3E%3Cbr%20/%3E%0A%0AGesch%C3%A4ftsstelle%20Bonn%3A%3Cbr%20/%3E%0APharma%20Deutschland%20e.V.%3Cbr%20/%3E%0AUbierstra%C3%9Fe%2071-73%2C%3Cbr%20/%3E%0A53173%20Bonn%2C%3Cbr%20/%3E%3Cbr%20/%3E%0A%0AGesch%C3%A4ftsstelle%20Br%C3%BCssel%3A%3Cbr%20/%3E%0APharma%20Deutschland%20e.V.%3Cbr%20/%3E%0ARue%20Marie%20de%20Bourgogne%2058%2C%3Cbr%20/%3E%0A1000%20Br%C3%BCssel%2C%3Chr%20/%3E%0A%0Awww.pharmadeutschland.de%20%3Chr/%3E%0ALinkedIn%3A%20https%3A//www.linkedin.com/company/pharmadeutschland/%3Chr/%3E%0AX%3A%20https%3A//x.com/PharmaDeu%3C/p%3E

%3Cp%3E%3Ci%3EInnovative%20Entdeckungen%20zu%20Biomarkern%20f%C3%BCr%20neurodegenerative%20Erkrankungen%20werden%20auf%20der%20internationalen%20Konferenz%20in%20%C3%BCber%2030%20Pr%C3%A4sentationen%20und%20Postern%20vorgestellt.%3C/i%3E%3C/p%3E%3Cp%3EAlamar%20Biosciences%2C%20ein%20Vorreiter%20im%20Bereich%20der%20Pr%C3%A4zisionsproteomik%2C%20hat%20heute%20bekannt%20gegeben%2C%20dass%20auf%20der%20AAIC-Konferenz%20vom%2027.%20bis%2031.%20Juli%20in%20Toronto%2C%20Kanada%2C%20Daten%20zur%20NULISA%E2%84%A2-Technologie%20in%20mehr%20als%2030%20wissenschaftlichen%20Sitzungen%20und%20Posterpr%C3%A4sentationen%20pr%C3%A4sentiert%20werden.%20Die%20NULISA-Plattform%20wird%20die%20Art%20und%20Weise%20revolutionieren%2C%20wie%20Biomarker%20erkannt%20werden%20und%20bietet%20eine%20un%C3%BCbertroffene%20Sensitivit%C3%A4t%20sowie%20Spezifit%C3%A4t%20bei%20der%20Multiplex-Detektion%20zur%20Diagnose%20und%20%C3%9Cberwachung%20von%20neurodegenerativen%20Erkrankungen.%20Auf%20dieser%20AAIC-Konferenz%20werden%20zum%20ersten%20Mal%20bedeutende%20klinische%20Daten%20pr%C3%A4sentiert%2C%20die%20mit%20NULISA%20zur%20Messung%20von%20pTau%20aus%20dem%20Gehirn%20sowie%20%C3%BCber%20120%20relevanten%20Proteinen%20im%20Zusammenhang%20mit%20Erkrankungen%20des%20zentralen%20Nervensystems%20gewonnen%20wurden.%20Diese%20Errungenschaft%20k%C3%B6nnte%20sowohl%20die%20fr%C3%BChzeitige%20Erkennung%20als%20auch%20das%20therapeutische%20Monitoring%20bei%20Alzheimer%20und%20%C3%A4hnlichen%20neurodegenerativen%20Krankheiten%20erheblich%20verbessern.%3C/p%3E%3Cp%3E%E2%80%9EDie%20Vorstellung%20der%20pTau-Daten%20aus%20dem%20Gehirn%20auf%20der%20AAIC%20unterstreicht%20die%20Leistungsf%C3%A4higkeit%20unserer%20NULISA-Technologie%20hinsichtlich%20Sensitivit%C3%A4t%20und%20Spezifit%C3%A4t%20sowie%20das%20Engagement%20unseres%20Teams%20f%C3%BCr%20die%20Weiterentwicklung%20von%20Biomarkern%20f%C3%BCr%20neurodegenerative%20Erkrankungen%E2%80%9C%2C%20erkl%C3%A4rte%20Dr.%20Yuling%20Luo%2C%20Gr%C3%BCnderin%2C%20Vorsitzende%20und%20CEO%20von%20Alamar%20Biosciences.%3C/p%3E%3Cp%3EDiese%20Daten%20werden%20am%20Montag%2C%20den%2028.%20Juli%20um%2013%3A20%20Uhr%20ET%20w%C3%A4hrend%20einer%20Produktpr%C3%A4sentation%20von%20Alamar%20vorgestellt.%20Zu%20den%20Referenten%20geh%C3%B6ren%20Prof.%20Jonathan%20Schott%20vom%20University%20College%20London%20sowie%20Dr.%20Cheryl%20Wellington%20von%20der%20University%20of%20British%20Columbia.%20Zu%20den%20Highlights%20z%C3%A4hlen%3A%3C/p%3E%3Cul%20%3E%3Cli%3E%3Cb%3EDaten%20zu%20pTau%20aus%20dem%20Gehirn%3A%3C/b%3E%20In%20dieser%20Pr%C3%A4sentation%20wird%20eine%20Geburtskohorte%20aus%20dem%20Jahr%201946%20behandelt%3B%20es%20zeigt%20neue%20Isoformen%20des%20pTau-Markers%20unter%20Verwendung%20des%20NULISAseq%E2%84%A2%20CNS%20Disease%20Panels%20in%20pr%C3%A4-symptomatischen%20Proben%20sowie%20nach%20AD-Diagnosen%20%E2%80%93%20dies%20hebt%20hervor%2C%20wie%20effektiv%20pTaus%20dabei%20sind%2C%20Alzheimer%20Jahre%20vor%20einer%20offiziellen%20Diagnose%20vorherzusagen.%3C/li%3E%3Cli%3E%3Cb%3EKorrelationen%20zum%20Krankheitsverlauf%3A%3C/b%3E%20Die%20Ergebnisse%20zeigen%20Zusammenh%C3%A4nge%20zwischen%20den%20Werten%20des%20gehirnabgeleiteten%20pTau-Markers%20sowie%20Amyloid-%20und%20Tau-PET-Bildgebungsdaten.%3C/li%3E%3Cli%3E%3Cb%3EBiomarker%20f%C3%BCr%20Neuropathologien%3A%20%3C/b%3EAnhand%20einer%20einzigartigen%20Kohorte%20autopsiebest%C3%A4tigter%20Patienten%20konnte%20mithilfe%20des%20NULISAseq%E2%84%A2%20CNS%20Disease%20Panels%20spezifische%20Biomarker%20identifiziert%20werden%20%E2%80%93%20diese%20erm%C3%B6glichen%20Nachweise%20%C3%BCber%20Neuropathologien%20ebenso%20wie%20AD-Komorbidit%C3%A4ten.%3C/li%3E%3Cli%3E%3Cb%3EAnwendung%20in%20pr%C3%A4klinischer%20Forschung%3A%20%3C/b%3EDass%20sich%20das%20NULISAseq%E2%84%A2%20Mouse%20Panel%20als%20n%C3%BCtzlich%20erwiesen%20hat%20bei%20Analysen%20an%20Plasma-%20oder%20Gehirnhomogenatproben%20verschiedener%20klinischer%20Modelle%20zur%20Alzheimer-Krankheit%20ist%20ebenfalls%20ein%20wichtiger%20Punkt.%3C/li%3E%3C/ul%3E%0A%3Cp%3EDie%20Alzheimer%27s%20Association%20International%20Conference%20%28AAIC%29%20gilt%20weltweit%20als%20f%C3%BChrendes%20Forum%20f%C3%BCr%20Wissenschaftlerinnen%20und%20Wissenschaftler%20im%20Bereich%20Demenzforschung%20inklusive%20Alzheimer-Forschung%3B%20j%C3%A4hrlich%20kommen%20hier%20Experten%20zusammen%20um%20neueste%20Erkenntnisse%20auszutauschen%20sowie%20Kooperationen%20zu%20f%C3%B6rdern%20%E2%80%93%20alles%20mit%20dem%20Ziel%20effektive%20Diagnostika%20oder%20Therapien%20voranzutreiben.%3C/p%3E%0A%3Cp%3EEinen%20vollst%C3%A4ndigen%20%C3%9Cberblick%20%C3%BCber%20alle%20Poster-%20und%20Vortragsthemen%20mit%20Bezug%20zu%20den%20pr%C3%A4sentierten%20NULISA-Daten%20finden%20Sie%20%3Ca%20href%3D%22hier%22%3Ehier%3C/a%3E.%3C/p%3E%0A%3Cp%20%3E%3Cstrong%3E%C3%9Cber%20Alamar%20Biosciences%20Inc.%3A%20%3C/strong%3E%3C/p%3E%0A%3Cp%20%3EAlamar%20Biosciences%20ist%20ein%20privates%20Biowissenschaftsunternehmen%20mit%20dem%20Ziel%20fortschrittliche%20Pr%C3%A4zisionsproteomik%20anzubieten%3B%20dies%20soll%20dazu%20beitragen%20Krankheiten%20so%20fr%C3%BCh%20wie%20m%C3%B6glich%20erkennen%20zu%20k%C3%B6nnen.%3Cbr%20/%3EDas%20firmeneigene%20System%20ARGO%20HT%20kombiniert%20nahtlos%20modernste%20genomische%20Fortschritte%20-%20gemeinsam%20erreichen%20sie%20eine%20Nachweisempfindlichkeit%20im%20Attomolbereich%3B%20damit%20stellt%20es%20derzeit%20die%20empfindlichste%20Technologie%20zum%20Nachweis%20von%20Proteinen%20dar.%3Cbr%20/%3EWeitere%20Informationen%20sind%20verf%C3%BCgbar%20unter%20%3Ca%20href%3D%22http%3A//alamarbio.com%22%3Ealamarbio.com%3C/a%3E.%3C/p%3E%0A%3Cp%3EBilder%20-%20%3Ca%20href%3D%22https%3A//mma.prnewswire.com/media/2738864/AAIC_2025_1.jpg%22%3EHier%20klicken%3C/a%3E%3C/p%3E%0A%3Cp%20%3ELogo%20-%20%3Ca%20href%3D%22https%3A//mma.prnewswire.com/media/1810182/Alamar_Logo_WhiteOutline_RGB_4x1_Logo_V1.jpg%22%3EHier%20klicken%3C/a%3E%3C/p%3E%0A%3Cp%20%3EUrspr%C3%BCnglicher%20Inhalt%20ansehen%3A%20%3Ca%20href%3D%22https%3A//www.prnewswire.com/news-releases/alamar-biosciences-prasentiert-bahnbrechende-aus-dem-gehirn-gewonnene-ptau-daten-auf-der-alzheimers-association-international-conference-aaic-302514723.html%22%3EHier%20klicken%3C/a%3E.%3C/p%3E%0A%3Cp%3EPressekontakt%3A%3C/P%20%3E%0A%3CP%20%3EApril%20Falcone%2C%3Cbr%20/%3EAlamar%20Biosciences%2C%3Cbr%20/%3E%20afalcone%40alamarbio.com%2C%3Cbr%20/%3E%28510%29%20838%E2%80%931783%3C/P%20%3E

%3Cp%3EDie%20Kintor%20Pharmaceutical%20Limited%20%28im%20Folgenden%20als%20%E2%80%9E%3Cb%3EUnternehmen%3C/b%3E%E2%80%9C%20bezeichnet%29%20freut%20sich%2C%20die%20ersten%20Ergebnisse%20der%20Phase%20II%20ihrer%20klinischen%20Hauptstudie%20zur%20neu%20entwickelten%20und%20potenziell%20f%C3%BChrenden%20KX-826%20Tinktur%20mit%201%2C0%20%25%20zur%20Behandlung%20von%20androgenetischer%20Alopezie%20%28AGA%29%20bekannt%20zu%20geben.%20Die%20Resultate%20belegen%2C%20dass%20die%20Phase%20II%20ihren%20prim%C3%A4ren%20Endpunkt%20erreicht%20hat%20und%20dabei%20sowohl%20statistisch%20signifikante%20als%20auch%20klinisch%20relevante%20Ergebnisse%20erzielt%20wurden%2C%20was%20auf%20eine%20hervorragende%20Wirksamkeit%20und%20Sicherheit%20hinweist.%20Die%20Analyse%20umfasste%2090%20Patienten%2C%20die%20an%20dieser%20Phase%20II%20Studie%20teilnahmen.%3C/p%3E%0A%0A%3Cul%3E%0A%3Cli%3EIn%20Bezug%20auf%20die%20Wirksamkeit%20zeigten%20sowohl%20die%20Gruppe%20mit%20der%200%2C5%20%25igen%20BID-Dosierung%20%28d.h.%20zweimal%20t%C3%A4glich%29%20als%20auch%20die%20Gruppe%20mit%20der%201%2C0%20%25igen%20BID-Dosierung%20im%20Vergleich%20zur%20Placebo-Gruppe%20eine%20statistisch%20signifikante%20therapeutische%20Wirkung%20sowie%20klinische%20Relevanz.%20Bei%20den%20Zielwerten%20f%C3%BCr%20die%20Anzahl%20der%20Areanon-Vellus-Haare%20%28%E2%80%9E%3Cb%3ETAHC%3C/b%3E%E2%80%9C%29%20konnte%20in%20der%200%2C5%20%25%20BID-Gruppe%20ein%20Anstieg%20von%2022%2C39%20Haaren/cm%C2%B2%20gegen%C3%BCber%20dem%20Ausgangswert%20festgestellt%20werden%3B%20in%20der%20Gruppe%20mit%20einer%20Dosierung%20von%201%2C0%20%25%20betrug%20dieser%20Anstieg%2021%2C87%20Haare/cm%C2%B2.%20Im%20Gegensatz%20dazu%20zeigte%20die%20Placebo-Gruppe%20lediglich%20einen%20Anstieg%20von%208%2C73%20Haaren/cm%C2%B2%20im%20Vergleich%20zum%20Ausgangswert.%20Der%20Unterschied%20zwischen%20den%20Gruppen%20war%20signifikant%3A%20Die%20TAHC-Zahl%20in%20der%20Gruppe%20mit%20einer%20Dosis%20von%200%2C5%25%20stieg%20um%20insgesamt%2013%2C66%20Haare/cm2%20im%20Vergleich%20zur%20Placebogruppe%20%28P%3D0.002%29%2C%20w%C3%A4hrend%20bei%20der%20Dosisgruppe%20von%201%25%20ein%20Zuwachs%20um%20durchschnittlich%2013.14%20Haare/cm2%20gegen%C3%BCber%20dem%20Placebo%20beobachtet%20wurde%20%28P%3D0.004%29.%20Zudem%20wiesen%20beide%20Gruppen%20deutliche%20Verbesserungen%20bei%20den%20Indikatoren%20f%C3%BCr%20das%20Haarwachstum%20%28%E2%80%9E%3Cb%3EHGA%3C/b%3E%E2%80%9C%29%20auf%3B%20diese%20waren%20ebenfalls%20signifikant%20besser%20als%20bei%20den%20Probanden%20aus%20der%20Placebo-Gruppe%3A%20Nach%20einer%20Behandlungsdauer%20von%20insgesamt24%20Wochen%20ergab%20sich%20f%C3%BCr%20den%20HGA-Indikator%20in%20der%20Gruppe%20mit%20einer%20Dosis%20von%20.5%25%20ein%20statistisch%20signifikanter%20Wert%20im%20Vergleich%20zur%20Kontrollgruppe%20%28P%20%3D%20.000%29%3B%20ebenso%20wies%20auch%20das%20HGA-Ergebnis%20ausderDosisgruppevon1%25signifikante%20Unterschiedeauf%28P%3D.013%29.%3C/li%3E%0A%3Cli%3EBzgl.derSicherheitsergebnissezeigtedieKX-826-Tinkturin%20dieserklinischenStudieneinezufriedenstellendeSicherheits-undVertr%C3%A4glichkeitmitgeringerInzidenzunerw%C3%BCnschterEreignisseinsgesamt.W%C3%A4hrenddesgesamtenStudienzeitraumswurdenkeinearzneimittelbedingtenNebenwirkungeninderFormvonsexuellenFunktionsst%C3%B6rungenbeobachtet%2CdaszeigtaufeinexzellentesSicherheitsprofilohneneuerscheinendeRisiken.%3C/li%3E%0A%3C/ul%3E%0A%0A%3Cp%3EDIEergebnissewurdenvondemunabh%C3%A4ngigenDaten%C3%BCberwachungsausschuss%28IDMC%29%C3%BCberpr%C3%BCft.Dessenprim%C3%A4reEmpfehlunglautete%2CdassdieklinischePhase-III-StudiebasiertaufdenaktuellenSicherheits-undWirksamkeitsdatenohne%C3%84nderungeninderBehandlungsgruppenoderStichprobengr%C3%B6%C3%9Fefortgesetztwerdenkann.%3C/p%3E%0A%0A%3Cp%3E%3Ca%20href%3D%22https%3A//www.prnewswire.com/de/pressemitteilungen/phase-ii-der-klinischen-hauptstudie-mit-kx-826-tinktur-1-0-zur-behandlung-von-mannlichen-erwachsenen-in-china-hat-den-primaren-endpunkt-erreicht-302514045.html%22%3EUrspr%C3%BCnglichen%20Inhalt%20anzeigen%3C/a%3E%3C/p%3E%0A%0A%3Cp%3EPressekontakt%3A%3C/p%3E%0A%3Cp%3EShengnan%20Zhang%2C%3Cbr%20/%3E%20snzhang%40kintor.com.cn%3C/p%3E

%60%60%60html%0A%3Cimg%20height%3D%27540%27%20with%3D%27720%27%20src%3D%27https%3A//cache.pressmailing.net/thumbnail/story_big/2ce9ba12-9737-42f8-8e8d-eb1ad50abb3f/premiere-in-bayern-neuer-hightech-computertomograph-am-campus-bad-neustadt-im-einsatz-bayerns-minist%27%20srcset%3D%27https%3A//cache.pressmailing.net/thumbnail/story_big/2ce9ba12-9737-42f8-8e8d-eb1ad50abb3f/premiere-in-bayern-neuer-hightech-computertomograph-am-campus-bad-neustadt-im-einsatz-bayerns-minist%20710w%2C%20https%3A//cache.pressmailing.net/thumbnail/story_small/2ce9ba12-9737-42f8-8e8d-eb1ad50abb3f/premiere-in-bayern-neuer-hightech-computertomograph-am-campus-bad-neustadt-im-einsatz-bayerns-minist%20532w%27%20sizes%3D%27%28min-width%3A%201360px%29%20720px%2C%20%28min-width%3A%201000px%29%2054.71vw%2C%20%28min-width%3A%20780px%29%20calc%2866.5vw%20-%2072px%29%2C%20calc%28100vw%20-%2048px%29%27%20alt%3D%27Premiere%20in%20Bayern%3A%20Neuer%20Hightech%20Computertomograph%20am%20Campus%20Bad%20Neustadt%20im%20Einsatz%20/%20Bayerns%20Ministerpr%C3%A4sident%20und%20Gesundheitsministerin%20besuchen%20Klinik%27%20class%3D%27single%27/%3E%0A%0A%3Cp%3EHeute%20wurde%20am%20RH%C3%96N-KLINIKUM%20Campus%20Bad%20Neustadt%20ein%20innovativer%20Photonenz%C3%A4hlender%20Computertomograph%20%28CT%29%20in%20Betrieb%20genommen%2C%20der%20die%20medizinische%20Diagnostik%20revolutioniert.%20Dieses%20hochmoderne%20Ger%C3%A4t%20geh%C3%B6rt%20zu%20den%20fortschrittlichsten%20seiner%20Art%20weltweit%20und%20ist%20das%20erste%20seiner%20Art%20in%20Bayern%20sowie%20eines%20von%20nur%20f%C3%BCnf%20Exemplaren%20in%20Deutschland.%20Die%20Klinik%20investierte%20etwa%203%2C5%20Millionen%20Euro%20f%C3%BCr%20technische%20Aufr%C3%BCstungen%20und%20Umbauten%2C%20wobei%20der%20Freistaat%20Bayern%20das%20Projekt%20mit%20finanziellen%20F%C3%B6rderungen%20unterst%C3%BCtzte.%3C/p%3E%0A%0A%3Cp%3EZur%20Einweihung%20des%20neuen%20Naeotom%20Alpha.Peak%20besuchten%20Bayerns%20Ministerpr%C3%A4sident%20Dr.%20Markus%20S%C3%B6der%20sowie%20die%20Staatsministerin%20f%C3%BCr%20Gesundheit%2C%20Pflege%20und%20Pr%C3%A4vention%20Judith%20Gerlach%20den%20Standort%20der%20Klinik%20im%20Norden%20Bayerns.%3C/p%3E%0A%0A%3Cp%3E%E2%80%9EWir%20m%C3%B6chten%20sicherstellen%2C%20dass%20jeder%20Zugang%20zu%20modernster%20Technologie%20hat.%20Daher%20ist%20es%20wichtig%2C%20dass%20medizinische%20Versorgung%20auf%20h%C3%B6chstem%20Niveau%20vor%20Ort%20gew%C3%A4hrleistet%20wird.%20Der%20Naeotom%20Alpha.Peak%20CT%20stellt%20ein%20herausragendes%20Beispiel%20f%C3%BCr%20Innovation%20aus%20Franken%20dar%E2%80%9C%2C%20erkl%C3%A4rte%20Ministerpr%C3%A4sident%20S%C3%B6der%20weiter%20und%20betonte%20die%20Bedeutung%20von%20Investitionen%20statt%20K%C3%BCrzungen%20im%20Gesundheitswesen%20mit%20einem%20j%C3%A4hrlichen%20Budget%20von%20%C3%BCber%20800%20Millionen%20Euro%20zur%20F%C3%B6rderung%20von%20Investitionskosten%20%E2%80%93%20eine%20Tendenz%20steigend.%3C/p%3E%0A%0A%3Cp%3EMinisterin%20Gerlach%20erg%C3%A4nzte%20dazu%3A%20%E2%80%9EModerne%20Standards%20erfordern%20kontinuierliche%20finanzielle%20Mittel%20f%C3%BCr%20Kliniken%3B%20daher%20liegt%20es%20uns%20am%20Herzen%20bayerische%20Krankenhaustr%C3%A4ger%20durch%20gezielte%20F%C3%B6rderma%C3%9Fnahmen%20zu%20unterst%C3%BCtzen.%E2%80%9C%20%3C/p%3E%0A%0A%3Cp%3EDer%20neue%20Photonenz%C3%A4hlende%20CT%20Naeotom%20Alpha.Peak%20erm%C3%B6glicht%20eine%20%C3%A4u%C3%9Ferst%20pr%C3%A4zise%20Bildgebung%20bei%20gleichzeitig%20reduzierter%20Strahlenbelastung.%20Dank%20seiner%20Geschwindigkeit%20und%20Detailtreue%20er%C3%B6ffnen%20sich%20neue%20M%C3%B6glichkeiten%20zur%20Fr%C3%BCherkennung%20sowie%20zur%20%C3%9Cberwachung%20verschiedener%20Krankheitsverl%C3%A4ufe%20und%20einer%20noch%20individuelleren%20Patientenversorgung.%3C/p%3E%0A%0A%3Cp%3E%22Mit%20dieser%20photonentechnologischen%20Innovation%20setzen%20wir%20einen%20wichtigen%20Schritt%20nach%20vorne%22%2C%20sagte%20Dr.%20Stefan%20Stranz%20vom%20Vorstand%20der%20RH%C3%96N-KLINIKUM%20AG%20%C3%BCber%20die%20zukunftsweisende%20Entwicklung%20des%20Campus%20zum%20Wohle%20aller%20Patienten.%3C/p%3E%0A%0A%3Cp%3EDr.%20Gunther%20K.%20Wei%C3%9F%20f%C3%BCgte%20hinzu%3A%20%E2%80%9ESeit%20mehr%20als%20f%C3%BCnf%20Jahrzehnten%20investieren%20wir%20kontinuierlich%20in%20medizinische%20Innovationen%20wie%20diesen%20neuen%20Photonenz%C3%A4hlenden%20CT.%E2%80%9C%20In%20diesem%20Jahr%20werden%20zudem%20an%20unseren%20Universit%C3%A4tskliniken%20Gie%C3%9Fen%20und%20Marburg%20jeweils%20ein%20Naeotom%20Alpha.Peak%20installiert%20werden%20nach%20dem%20bereits%20erfolgten%20Einsatz%20am%20Campus%20Bad%20Neustadt%20sowie%20an%20der%20Zentralklinik%20Bad%20Berka%20in%20Th%C3%BCringen.%E2%80%9D%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EKundenvorteile%3C/b%3E%3C/p%3E%0A%20%20%0A%3Cp%3EDaraus%20ergeben%20sich%20zahlreiche%20Vorteile%20f%C3%BCr%20die%20Patienten%3B%20so%20ist%20beispielsweise%20die%20Strahlenbelastung%20im%20Vergleich%20zu%20herk%C3%B6mmlichen%20Ger%C3%A4ten%20erheblich%20gesenkt%20worden%20%E2%80%93%20was%20den%20Schutz%20ihrer%20Gesundheit%20priorisiert.%3C/p%3E%0A%20%20%0A%3Cp%3EZudem%20verk%C3%BCrzt%20sich%20auch%20die%20Dauer%20der%20Untersuchungen%20erheblich%3B%20Notfallpatienten%20k%C3%B6nnen%20beispielsweise%20innerhalb%20weniger%20als%20einer%20Sekunde%20vollst%C3%A4ndig%20gescannt%20werden.%3C/p%3E%0A%20%20%0A%3Cp%3E%22Mit%20diesem%20neuen%20System%20erzielen%20wir%20einen%20Quantensprung%20in%20der%20Diagnostik%22%2C%20erkl%C3%A4rte%20PD%20Dr.med.Lukas%20Lehmkuhl%20vom%20Chefarztbereich%20Diagnostische%20Radiologie%20am%20Campus%20Bad%20Neustadt.%3Cbr%20/%3E%20%22Selbst%20kleinste%20Ver%C3%A4nderungen%20k%C3%B6nnen%20nun%20sichtbar%20gemacht%20werden%20%E2%80%93%20dies%20hilft%20uns%20Krankheiten%20fr%C3%BChzeitig%20zu%20erkennen.%22%20%3C/p%3E%0A%20%20%0A%3Cp%3EDas%20neuartige%20System%20wandelt%20R%C3%B6ntgenphotonen%20direkt%20in%20elektrische%20Signale%20um%20ohne%20Umweg%20%C3%BCber%20Lichtsignale%3B%20dadurch%20entstehen%20klinisch%20hochwertige%20Bilder%20mit%20hoher%20Aufl%C3%B6sung%20ohne%20elektronisches%20Rauschen%20sowie%20verbessertem%20Kontrast%20verglichen%20mit%20traditionellen%20CT-Aufnahmen%20%E2%80%93%20was%20m%C3%B6glicherweise%20invasive%20Eingriffe%20vermeiden%20kann.%3Cbr%20/%3E%20Dies%20stellt%20eine%20positive%20Nachricht%20f%C3%BCr%20viele%20Patienten%20dar%21%3C/p%3E%0A%20%20%0A%20%3CP%3EThe%20Naeotom%20Alpha.Peak%20wurde%20lokal%20entwickelt%20etwa%20hundert%20Kilometer%20entfernt%20vom%20Campus%20Forchheim%20hergestellt.%3Cbr%20/%3E%22Siemens%20Healthineers%20hat%20mehr%20als%20zwei%20Jahrzehnte%20daran%20gearbeitet%20diese%20photonenz%C3%A4hlende%20Technologie%20marktreif%20zu%20machen%22%2C%20erl%C3%A4uterte%20Dr.Philipp%20Fischer%20von%20Siemens%20Healthineers.%22Unser%20Ziel%20ist%20es%20durch%20unsere%20neuesten%20Ger%C3%A4tegeneration%20Menschenleben%20weltweit%20positiv%20beeinflussen%22.%3C/P%3E%0A%20%0A%20%3CP%3EAnwendungsgebiete%20des%20Photon-Z%C3%A4hlenden%20CT%20kommen%20interdisziplin%C3%A4ren%20Teams%20verschiedenster%20Fachrichtungen%20zugute%20insbesondere%20Herzmedizin%20Neurologie%20muskuloskelettalen%20Medizin%20oder%20Notfalldiagnosen.%3Cbr%20/%3E%22F%C3%BCr%20kardiologische%20Anwendungen%20erm%C3%B6glichen%20spezielle%20Bildgebungsverfahren%20zusammen%20mit%20KI-basierter%20Softwarel%C3%B6sungen%20v%C3%B6llig%20neue%20Perspektiven%20bei%20Herzuntersuchungen%2C%22%20so%20Lehmkuhl%20weiter.%22%3C/P%3E%0A%20%0A%20%3CP%3E%3Cb%3EKlinikangebot%3C/b%3E%3C/P%3E%0A%20%0A%20%3CP%3E%3Cb%3EKlinik%20f%C3%BCr%20diagnostische%20Interventionelle%20Radiologie%20Neuroradiologie%3A%3C/b%3E%3Cbr%20/%3E%0A%20Diese%20Abteilung%20gew%C3%A4hrleistet%20umfassende%20radiologische%20Versorgung%20s%C3%A4mtlicher%20klinischer%20Disziplinen%20einschlie%C3%9Flich%20zentraler%20Notaufnahme%20unter%20Leitung%20PD%20Dr.med.Lukas%20Lehmkuhl%20%28Diagnostik%29%26nbsp%3B%26nbsp%3B%26nbsp%3B%26nbsp%3B%26nbsp%3B%26nbsp%3B%3Cstrong%3E%26%20Prof.Dr.med.Andr%C3%A9%20Kemmling%26nbsp%3B%28Intervention%29%3C/strong%3E.%20J%C3%A4hrlich%20finden%20hier%20rund%20%26nbsp%3B50000%20R%C3%B6ntgen%2C%26nbsp%3B18000CT-%26amp%20%3B7000%20MRT-Untersuchungen%20statt.%26lt%3B/%20P%26gt%3B%3C/%20P%20%3E%0A%20%0A%3CP%20%3E%3CB%20%3ERH%C3%96N-KLINIKUM%20AG%20%3A%3C/%20B%20%3E%20%26lt%3Bbr%20/%26gt%3B%0A%20Eines%20gr%C3%B6%C3%9Ften%20Gesundheitsdienstleister%20Deutschlands.%26lt%3Bbr%20/%26gt%3B%0A%20An%20f%C3%BCnf%20Standorten%20erhalten%20j%C3%A4hrlich%20ca.%3B913000Patienten%20Behandlung.%26lt%3Bbr%20/%26gt%3B%0A%20%C3%9Cber18700Mitarbeiter%20sind%20besch%C3%A4ftigt.Das%20innovative%20Konzept%20verfolgt%20sektoren%C3%BCbergreifender%20Versorgung%20l%C3%A4ndlicher%20Regionen%20fortlaufend%20digitale%20Transformation%20Unternehmensstrategie%20umfasst%20strategischen%20Partnerschaften%20.%3CBR%20/%3E%3CBR%20/%3E%3C/%20P%20%3E%0A%0A%3CP%3EPressekontakt%3A%3C/%20p%20%3E%0A%3CP%20%3ERH%C3%96N-KLINIKUM%20AG%20%7C%20Unternehmenskommunikation%20Marketing%3Cbr%20/%3E%0AHeike%20Ochmann%20%7C%20T.%2B49%26nbsp%20%3B97716512130%7C%20heike%20ochmann%40rhoenklinkum-ag.com%3Cbr%20/%3E%3C%20br%20/%3E%0ARH%C3%96N-KLINIKUM%20CAMPUS%20BAD%20NEUSTADT%7C%20Kommunikation%3Cbr%20/%3E%0AKatrin%20Schmitt%20%7CT.%2B49%26nbsp%20%3B97716626100%7C%20kommunikation%40campusnes.de%20%3C/%20p%20%3E%0A%60%60%60

%3Cp%3E%E4%BB%8A%E5%A4%A9%EF%BC%8C%E4%BD%8D%E4%BA%8E%E5%B7%B4%E5%BE%B7%E7%BA%BD%E6%96%BD%E5%A1%94%E7%89%B9%E7%9A%84RH%C3%96N-KLINIKUM%E6%A0%A1%E5%9B%AD%E6%AD%A3%E5%BC%8F%E5%90%AF%E7%94%A8%E4%BA%86%E4%B8%80%E5%8F%B0%E6%96%B0%E5%9E%8B%E7%9A%84%E5%85%89%E5%AD%90%E8%AE%A1%E6%95%B0%E8%AE%A1%E7%AE%97%E6%9C%BA%E6%96%AD%E5%B1%82%E6%89%AB%E6%8F%8F%E4%BB%AA%EF%BC%88CT%EF%BC%89%EF%BC%8C%E8%BF%99%E5%B0%86%E5%8C%BB%E5%AD%A6%E8%AF%8A%E6%96%AD%E6%8F%90%E5%8D%87%E5%88%B0%E4%B8%80%E4%B8%AA%E5%85%A8%E6%96%B0%E7%9A%84%E9%AB%98%E5%BA%A6%E3%80%82%E8%BF%99%E5%8F%B0%E8%AE%BE%E5%A4%87%E6%98%AF%E5%85%A8%E7%90%83%E6%9C%80%E5%85%88%E8%BF%9B%E7%9A%84%E4%B9%8B%E4%B8%80%EF%BC%8C%E5%9C%A8%E5%BE%B7%E5%9B%BD%E4%BB%85%E6%9C%89%E4%BA%94%E5%8F%B0%EF%BC%8C%E8%80%8C%E5%AE%83%E4%B9%9F%E6%98%AF%E5%B7%B4%E4%BC%90%E5%88%A9%E4%BA%9A%E5%B7%9E%E9%A6%96%E5%8F%B0%E3%80%82%E5%8C%BB%E9%99%A2%E5%9C%A8%E6%94%B9%E5%BB%BA%E5%92%8C%E6%8A%80%E6%9C%AF%E4%B8%8A%E6%8A%95%E8%B5%84%E4%BA%86%E7%BA%A6350%E4%B8%87%E6%AC%A7%E5%85%83%EF%BC%8C%E5%B7%B4%E4%BC%90%E5%88%A9%E4%BA%9A%E5%B7%9E%E6%94%BF%E5%BA%9C%E4%B9%9F%E4%B8%BA%E8%AF%A5%E9%A1%B9%E7%9B%AE%E6%8F%90%E4%BE%9B%E4%BA%86%E8%B5%84%E9%87%91%E6%94%AF%E6%8C%81%E3%80%82%3C/p%3E%0A%0A%3Cp%3E%E5%9C%A8%E6%96%B0%E8%AE%BE%E5%A4%87Naeotom%20Alpha.Peak%E6%8A%95%E5%85%A5%E4%BD%BF%E7%94%A8%E4%B9%8B%E9%99%85%EF%BC%8C%E5%B7%B4%E4%BC%90%E5%88%A9%E4%BA%9A%E5%B7%9E%E6%80%BB%E7%90%86%E9%A9%AC%E5%BA%93%E6%96%AF%C2%B7%E7%B4%A2%E5%BE%B7%E5%8D%9A%E5%A3%AB%E5%8F%8A%E5%8D%AB%E7%94%9F%E3%80%81%E6%8A%A4%E7%90%86%E4%B8%8E%E9%A2%84%E9%98%B2%E4%BA%8B%E5%8A%A1%E9%83%A8%E9%95%BF%E6%9C%B1%E8%BF%AA%E6%80%9D%C2%B7%E6%A0%BC%E6%8B%89%E8%B5%AB%E8%AE%BF%E9%97%AE%E4%BA%86%E4%BD%8D%E4%BA%8E%E5%8C%97%E9%83%A8%E7%9A%84%E8%BF%99%E5%AE%B6%E5%8C%BB%E9%99%A2%E3%80%82%3C/p%3E%0A%0A%3Cp%3E%E7%B4%A2%E5%BE%B7%E6%80%BB%E7%90%86%E8%A1%A8%E7%A4%BA%EF%BC%9A%E2%80%9C%E6%88%91%E4%BB%AC%E5%B8%8C%E6%9C%9B%E6%AF%8F%E4%B8%AA%E4%BA%BA%E9%83%BD%E8%83%BD%E4%BA%AB%E5%8F%97%E5%88%B0%E6%9C%80%E6%96%B0%E7%A7%91%E6%8A%80%E5%B8%A6%E6%9D%A5%E7%9A%84%E5%A5%BD%E5%A4%84%E3%80%82%E5%9B%A0%E6%AD%A4%EF%BC%8C%E6%88%91%E4%BB%AC%E5%BF%85%E9%A1%BB%E7%A1%AE%E4%BF%9D%E5%8C%BB%E7%96%97%E6%9C%8D%E5%8A%A1%E8%83%BD%E5%A4%9F%E5%B0%B1%E8%BF%91%E6%8F%90%E4%BE%9B%EF%BC%8C%E5%B9%B6%E4%BF%9D%E6%8C%81%E9%AB%98%E6%B0%B4%E5%B9%B3%E3%80%82Naeotom%20Alpha.Peak%20CT%E6%98%AF%E7%9B%AE%E5%89%8D%E9%A1%B6%E5%B0%96%E8%AE%BE%E5%A4%87%E4%B9%8B%E4%B8%80%EF%BC%8C%E6%98%AF%E5%BC%97%E5%85%B0%E8%82%AF%E5%9C%B0%E5%8C%BA%E5%88%9B%E6%96%B0%E7%9A%84%E6%9D%B0%E5%87%BA%E4%BB%A3%E8%A1%A8%E3%80%82%E5%9C%A8%E5%B7%B4%E4%BC%90%E5%88%A9%E4%BA%9A%EF%BC%8C%E6%88%91%E4%BB%AC%E6%B3%A8%E9%87%8D%E6%8A%95%E8%B5%84%EF%BC%8C%E8%80%8C%E4%B8%8D%E6%98%AF%E5%89%8A%E5%87%8F%E5%8C%BB%E9%99%A2%E6%95%B0%E9%87%8F%E3%80%82%E6%88%91%E4%BB%AC%E7%9A%84%E6%8A%95%E8%B5%84%E8%A1%A5%E5%8A%A9%E6%AF%8F%E5%B9%B4%E8%B6%85%E8%BF%878%E4%BA%BF%E6%AC%A7%E5%85%83%EF%BC%8C%E5%B9%B6%E4%B8%94%E8%BF%98%E5%9C%A8%E4%B8%8D%E6%96%AD%E5%A2%9E%E5%8A%A0%E3%80%82%E8%BF%99%E9%A1%B9%E5%80%A1%E8%AE%AE%E7%89%B9%E5%88%AB%E6%83%A0%E5%8F%8A%E5%86%9C%E6%9D%91%E5%9C%B0%E5%8C%BA%EF%BC%8C%E8%AE%A9%E5%BD%93%E5%9C%B0%E5%B1%85%E6%B0%91%E8%83%BD%E5%A4%9F%E6%96%B9%E4%BE%BF%E5%9C%B0%E8%8E%B7%E5%BE%97%E5%8C%BB%E7%96%97%E6%9C%8D%E5%8A%A1%E3%80%82%E6%88%91%E8%A1%B7%E5%BF%83%E6%84%9F%E8%B0%A2%E6%89%80%E6%9C%89%E5%8C%BB%E5%8A%A1%E5%B7%A5%E4%BD%9C%E8%80%85%E5%92%8C%E6%8A%A4%E7%90%86%E4%BA%BA%E5%91%98%EF%BC%8C%E4%BB%96%E4%BB%AC%E6%97%A0%E7%A7%81%E5%A5%89%E7%8C%AE%EF%BC%8C%E4%B8%BA%E4%BB%96%E4%BA%BA%E6%9C%8D%E5%8A%A1%E3%80%82%E2%80%9D%3C/p%3E%0A%0A%3Cp%3E%E6%A0%BC%E6%8B%89%E8%B5%AB%E9%83%A8%E9%95%BF%E8%A1%A5%E5%85%85%E9%81%93%EF%BC%9A%E2%80%9C%E7%8E%B0%E4%BB%A3%E5%8C%96%E6%A0%87%E5%87%86%E8%A6%81%E6%B1%82%E5%8C%BB%E9%99%A2%E6%8C%81%E7%BB%AD%E8%BF%9B%E8%A1%8C%E6%8A%95%E8%B5%84%E3%80%82%E5%9B%A0%E6%AD%A4%EF%BC%8C%E6%94%AF%E6%8C%81%E5%8C%BB%E9%99%A2%E7%AE%A1%E7%90%86%E8%80%85%E9%80%9A%E8%BF%87%E6%9C%89%E6%95%88%E8%B5%84%E5%8A%A9%E6%9D%A5%E5%AE%9E%E7%8E%B0%E8%BF%99%E4%B8%80%E7%9B%AE%E6%A0%87%EF%BC%8C%E6%98%AF%E6%88%91%E4%BB%AC%E5%81%A5%E5%BA%B7%E6%94%BF%E7%AD%96%E7%9A%84%E9%87%8D%E8%A6%81%E4%BB%BB%E5%8A%A1%E3%80%82%E2%80%9D%3C/p%3E%0A%0A%3Cp%3E%E6%96%B0%E6%8E%A8%E5%87%BA%E7%9A%84%E5%85%89%E5%AD%90CT%20Naeotom%20Alpha.Peak%E5%85%B7%E5%A4%87%E9%AB%98%E7%B2%BE%E5%BA%A6%E6%88%90%E5%83%8F%E8%83%BD%E5%8A%9B%EF%BC%8C%E5%90%8C%E6%97%B6%E6%98%BE%E8%91%97%E9%99%8D%E4%BD%8E%E8%BE%90%E5%B0%84%E5%89%82%E9%87%8F%E3%80%82%E5%85%B6%E5%BF%AB%E9%80%9F%E6%80%A7%E5%92%8C%E7%BB%86%E8%8A%82%E6%B8%85%E6%99%B0%E5%BA%A6%E4%B8%BA%E5%A4%9A%E7%A7%8D%E7%96%BE%E7%97%85%E7%9A%84%E6%97%A9%E6%9C%9F%E5%8F%91%E7%8E%B0%E5%92%8C%E7%97%85%E7%A8%8B%E7%9B%91%E6%B5%8B%E5%BC%80%E8%BE%9F%E4%BA%86%E6%96%B0%E7%9A%84%E5%8F%AF%E8%83%BD%E6%80%A7%EF%BC%8C%E4%BB%8E%E8%80%8C%E5%AE%9E%E7%8E%B0%E6%9B%B4%E4%B8%AA%E6%80%A7%E5%8C%96%E7%9A%84%E6%82%A3%E8%80%85%E6%8A%A4%E7%90%86%E3%80%82%3C/p%3E%0A%0A%3Cp%3ERH%C3%96N-KLINIKUM%20AG%E8%91%A3%E4%BA%8B%E4%BC%9A%E6%88%90%E5%91%98%E6%96%AF%E7%89%B9%E5%87%A1%C2%B7%E6%96%AF%E7%89%B9%E6%9C%97%E5%85%B9%E5%8D%9A%E5%A3%AB%E8%A1%A8%E7%A4%BA%EF%BC%9A%E2%80%9C%E9%80%9A%E8%BF%87%E5%85%89%E5%AD%90%E6%8A%80%E6%9C%AF%EF%BC%8C%E6%88%91%E4%BB%AC%E5%9C%A8%E5%B7%B4%E5%BE%B7%E7%BA%BD%E6%96%BD%E5%A1%94%E7%89%B9%E5%BC%80%E5%90%AF%E4%BA%86%E4%B8%80%E4%B8%AA%E5%B4%AD%E6%96%B0%E7%9A%84%E7%AF%87%E7%AB%A0%E3%80%82%E8%BF%99%E5%90%91%E6%9C%AA%E6%9D%A5%E5%8F%91%E5%B1%95%E4%BB%A5%E5%8F%8A%E6%A0%A1%E5%9B%AD%E5%8A%A8%E6%80%81%E8%BF%9B%E6%AD%A5%E5%8F%91%E5%87%BA%E4%BA%86%E5%BC%BA%E7%83%88%E4%BF%A1%E5%8F%B7%EF%BC%8C%E4%BB%A5%E9%80%A0%E7%A6%8F%E6%88%91%E4%BB%AC%E7%9A%84%E6%82%A3%E8%80%85%E3%80%82%E2%80%9D%3C/p%3E%0A%0A%3Cp%3ERH%C3%96N-KLINIKUM%20AG%E8%91%A3%E4%BA%8B%E4%BC%9A%E6%88%90%E5%91%98%E5%8F%A4%E6%81%A9%E7%89%B9%C2%B7K.%20%E7%BB%B4%E6%96%AF%E5%8D%9A%E5%A3%AB%E8%A1%A5%E5%85%85%E8%AF%B4%EF%BC%9A%E2%80%9C%E6%88%91%E4%BB%AC%E5%B7%B2%E7%BB%8F%E5%9C%A8%E5%85%AC%E5%8F%B850%E5%B9%B4%E7%9A%84%E5%8E%86%E5%8F%B2%E4%B8%AD%E6%8C%81%E7%BB%AD%E6%8A%95%E5%85%A5%E5%8C%BB%E5%AD%A6%E5%88%9B%E6%96%B0%EF%BC%8C%E5%9B%A0%E6%AD%A4%E4%B9%9F%E5%8C%85%E6%8B%AC%E6%96%B0%E7%9A%84%E5%85%89%E5%AD%90%E8%AE%A1%E6%95%B0CT%E3%80%82%E4%BB%8A%E5%B9%B4%E6%99%9A%E4%BA%9B%E6%97%B6%E5%80%99%EF%BC%8C%E5%9C%A8%E9%BB%91%E6%A3%AE%E5%B7%9E%E5%90%89%E6%A3%AE%E5%92%8C%E9%A9%AC%E5%B0%94%E5%A0%A1%E4%B8%A4%E6%89%80%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E5%8C%BB%E9%99%A2%E4%B8%AD%EF%BC%8C%E6%88%91%E4%BB%AC%E5%B0%86%E5%90%84%E8%87%AA%E5%90%AF%E7%94%A8%E4%B8%80%E5%8F%B0Naeotom%20Alpha.Peak%E3%80%82%E2%80%9D%3C/p%3E%0A%0A%3Cp%3E%3Cb%3E%E5%AF%B9%E6%82%A3%E8%80%85%E8%80%8C%E8%A8%80%E7%9A%84%E6%96%B0%E4%BC%98%E5%8A%BF%3C/b%3E%3C/p%3E%0A%20%20%0A%3Cp%3E%E5%AF%B9%E4%BA%8E%E6%82%A3%E8%80%85%E6%9D%A5%E8%AF%B4%EF%BC%8C%E8%BF%99%E6%84%8F%E5%91%B3%E7%9D%80%E8%AE%B8%E5%A4%9A%E5%A5%BD%E5%A4%84%E3%80%82%E4%B8%8E%E4%BC%A0%E7%BB%9F%E8%AE%BE%E5%A4%87%E7%9B%B8%E6%AF%94%EF%BC%8C%E8%BE%90%E5%B0%84%E5%89%82%E9%87%8F%E6%98%BE%E8%91%97%E9%99%8D%E4%BD%8E%EF%BC%8C%E6%9B%B4%E5%8A%A0%E5%85%B3%E6%B3%A8%E4%BB%96%E4%BB%AC%E7%9A%84%E5%AE%89%E5%85%A8%E4%B8%8E%E8%88%92%E9%80%82%E3%80%82%E6%AD%A4%E5%A4%96%EF%BC%8C%E6%9B%B4%E7%9F%AD%E7%9A%84%E6%A3%80%E6%9F%A5%E6%97%B6%E9%97%B4%E4%B9%9F%E6%98%AF%E4%B8%80%E5%A4%A7%E4%BA%AE%E7%82%B9%E3%80%82%E4%BE%8B%E5%A6%82%EF%BC%8C%E5%AF%B9%E4%BA%8E%E6%80%A5%E6%95%91%E7%97%85%E4%BA%BA%EF%BC%8C%E4%B8%80%E4%B8%AA%E5%AE%8C%E6%95%B4%E6%89%AB%E6%8F%8F%E5%8F%AF%E4%BB%A5%E5%9C%A8%E4%B8%8D%E5%88%B0%E4%B8%80%E7%A7%92%E9%92%9F%E5%86%85%E5%AE%8C%E6%88%90%E3%80%82%3C/p%3E%0A%20%20%0A%3Cp%3E%22%E5%80%9F%E5%8A%A9%E8%BF%99%E4%B8%80%E6%96%B0%E7%B3%BB%E7%BB%9F%EF%BC%8C%E6%88%91%E4%BB%AC%E5%B0%86%E5%9C%A8%E8%AF%8A%E6%96%AD%E9%A2%86%E5%9F%9F%E5%8F%96%E5%BE%97%E8%B4%A8%E5%8F%98%E7%AA%81%E7%A0%B4%EF%BC%8C%E4%BD%BF%E5%BE%97%E5%8D%B3%E4%BD%BF%E6%98%AF%E5%BE%AE%E5%B0%8F%E4%B8%94%E4%BC%A0%E7%BB%9FCT%E6%8A%80%E6%9C%AF%E9%9A%BE%E4%BB%A5%E8%AF%86%E5%88%AB%E7%9A%84%E9%97%AE%E9%A2%98%E4%B9%9F%E8%83%BD%E8%A2%AB%E6%B8%85%E6%99%B0%E5%91%88%E7%8E%B0%E3%80%82%E8%BF%99%E5%B8%AE%E5%8A%A9%E6%88%91%E4%BB%AC%E6%9B%B4%E6%97%A9%E5%9C%B0%E5%8F%91%E7%8E%B0%E7%96%BE%E7%97%85%EF%BC%8C%E5%B9%B6%E8%BF%85%E9%80%9F%E5%81%9A%E5%87%BA%E6%9B%B4%E5%8A%A0%E7%B2%BE%E5%87%86%E7%9A%84%E8%AF%8A%E6%96%AD%EF%BC%8C%E2%80%9D%E8%AF%8A%E6%96%AD%E6%94%BE%E5%B0%84%E7%A7%91%E4%B8%BB%E4%BB%BB%E5%8D%A2%E5%8D%A1%E6%96%AF%C2%B7%E8%8E%B1%E5%A7%86%E5%BA%93%E5%B0%94PD%E5%8C%BB%E7%94%9F%E8%AF%B4%E9%81%93%E3%80%82%3C/p%3E%0A%20%20%0A%3Cp%3E%E8%AF%A5%E7%B3%BB%E7%BB%9F%E8%83%BD%E5%A4%9F%E7%9B%B4%E6%8E%A5%E5%B0%86X%E5%B0%84%E7%BA%BF%E5%85%89%E5%AD%90%E8%BD%AC%E5%8C%96%E4%B8%BA%E7%94%B5%E4%BF%A1%E5%8F%B7%EF%BC%8C%E6%97%A0%E9%9C%80%E7%BB%8F%E8%BF%87%E8%BD%AC%E6%8D%A2%E6%88%90%E5%85%89%E4%BF%A1%E5%8F%B7%E8%BF%99%E4%B8%80%E7%8E%AF%E8%8A%82%E3%80%82%E5%9B%A0%E6%AD%A4%EF%BC%8C%E5%85%B6%E7%94%9F%E6%88%90%E4%B8%B4%E5%BA%8A%E5%9B%BE%E5%83%8F%E5%85%B7%E6%9C%89%E6%9E%81%E9%AB%98%E5%88%86%E8%BE%A8%E7%8E%87%EF%BC%8C%E6%B2%A1%E6%9C%89%E7%94%B5%E5%AD%90%E5%99%AA%E5%A3%B0%EF%BC%8C%E7%9B%B8%E8%BE%83%E4%BA%8E%E4%BC%A0%E7%BB%9FCT%E5%BD%B1%E5%83%8F%E6%98%BE%E7%A4%BA%E5%87%BA%E6%9B%B4%E5%A5%BD%E7%9A%84%E5%AF%B9%E6%AF%94%E5%BA%A6%E3%80%82%E8%BF%99%E4%BA%9B%E7%B2%BE%E7%A1%AE%E7%9A%84%E4%BF%A1%E6%81%AF%E5%8F%AF%E8%83%BD%E4%BD%BF%E6%9F%90%E4%BA%9B%E4%BE%B5%E5%85%A5%E6%80%A7%E6%A3%80%E6%9F%A5%E5%BE%97%E4%BB%A5%E9%81%BF%E5%85%8D%EF%BC%8C%E5%AF%B9%E6%82%A3%E8%80%85%E6%9D%A5%E8%AF%B4%E6%97%A0%E7%96%91%E6%98%AF%E4%B8%80%E5%A4%A7%E5%88%A9%E5%A5%BD%E6%B6%88%E6%81%AF%E3%80%82%3C/p%3E%0A%20%20%0A%3Cp%3ENaeotom%20Alpha.Peak%E6%98%AF%E5%9C%A8%E5%BE%B7%E5%9B%BD%E5%BC%80%E5%8F%91%E5%B9%B6%E5%88%B6%E9%80%A0%EF%BC%8C%E4%BB%85%E8%B7%9D%E6%A0%A1%E5%9B%AD%E7%BA%A6100%E5%85%AC%E9%87%8C%EF%BC%8C%E7%94%B1%E8%A5%BF%E9%97%A8%E5%AD%90%E5%81%A5%E5%BA%B7%E7%A7%91%E6%8A%80%E5%85%AC%E5%8F%B8%E7%94%9F%E4%BA%A7%E3%80%82%E2%80%9C%E8%A5%BF%E9%97%A8%E5%AD%90%E5%81%A5%E5%BA%B7%E7%A7%91%E6%8A%80%E8%8A%B1%E8%B4%B920%E5%A4%9A%E5%B9%B4%E6%97%B6%E9%97%B4%E5%B0%86%E8%BF%99%E7%A7%8D%20photon-counting%20CT%20%E6%8A%80%E6%9C%AF%E6%8E%A8%E5%90%91%E5%B8%82%E5%9C%BA%E6%88%90%E7%86%9F%E9%98%B6%E6%AE%B5%E3%80%82%E6%88%91%E4%BB%AC%E7%9A%84%E7%9B%AE%E6%A0%87%E6%98%AF%E5%88%A9%E7%94%A8%E6%9C%80%E6%96%B0%E4%B8%80%E4%BB%A3%E8%AE%BE%E5%A4%87%EF%BC%8C%E4%BB%A5%E6%9C%80%E9%AB%98%E7%B2%BE%E5%BA%A6%E6%8F%8F%E7%BB%98%E4%BA%BA%E4%BD%93%E7%BB%93%E6%9E%84%EF%BC%8C%E5%AE%9E%E7%8E%B0%E6%97%A9%E6%9C%9F%E7%96%BE%E7%97%85%E8%AF%86%E5%88%AB%E5%B9%B6%E4%BF%83%E8%BF%9B%E4%B8%AA%E4%BD%93%E5%8C%96%E6%B2%BB%E7%96%97%EF%BC%8C%E4%BB%8E%E8%80%8C%E6%94%B9%E5%96%84%E6%95%B0%E4%BA%BF%E4%BA%BA%E7%9A%84%E7%94%9F%E6%B4%BB%E8%B4%A8%E9%87%8F%E3%80%82%E5%90%8C%E6%97%B6%EF%BC%8C%E4%B8%8ERH%C3%96N-KLINIKUM%20Campus%20Bad%20Neustadt%E4%B9%8B%E9%97%B4%E9%95%BF%E6%9C%9F%E4%BB%A5%E6%9D%A5%E5%BB%BA%E7%AB%8B%E8%B5%B7%E6%88%90%E5%8A%9F%E5%90%88%E4%BD%9C%E5%85%B3%E7%B3%BB%EF%BC%8C%E5%B0%86%E7%BB%A7%E7%BB%AD%E6%B7%B1%E5%8C%96%EF%BC%8C%E2%80%9D%E8%A5%BF%E9%97%A8%E5%AD%90%E5%81%A5%E5%BA%B7%E7%A7%91%E6%8A%80%E5%85%AC%E5%8F%B8CT%E4%B8%9A%E5%8A%A1%E9%83%A8%E9%97%A8%E8%B4%9F%E8%B4%A3%E4%BA%BA%E8%8F%B2%E5%88%A9%E6%99%AE%C2%B7%E8%B4%B9%E8%88%8D%E5%B0%94%E5%8D%9A%E5%A3%AB%E8%A1%A8%E7%A4%BA%E3%80%82%3C/p%3E%0A%20%20%0A%3Cp%3ENaeotom%20Alpha.Peak%E5%B9%BF%E6%B3%9B%E5%BA%94%E7%94%A8%E4%BA%8E%E4%B8%8D%E5%90%8C%E4%B8%93%E4%B8%9A%E9%A2%86%E5%9F%9F%EF%BC%8C%E5%8C%85%E6%8B%AC%E5%BF%83%E8%84%8F%E5%8C%BB%E5%AD%A6%E3%80%81%E7%A5%9E%E7%BB%8F%E5%8C%BB%E5%AD%A6%E3%80%81%E8%82%8C%E8%82%89%E9%AA%A8%E9%AA%BC%E5%8C%BB%E5%AD%A6%E4%BB%A5%E5%8F%8A%E6%80%A5%E6%95%91%E8%AF%8A%E6%96%AD%E7%AD%89%E5%AD%A6%E7%A7%91%EF%BC%8C%E4%B8%BA%E8%B7%A8%E5%AD%A6%E7%A7%91%E5%9B%A2%E9%98%9F%E5%B8%A6%E6%9D%A5%E4%BA%86%E8%AF%B8%E5%A4%9A%E7%9B%8A%E5%A4%84%E3%80%82%E2%80%9C%E5%AF%B9%E4%BA%8E%E5%BF%83%E8%84%8F%E7%97%85%E5%AD%A6%EF%BC%8C%E9%80%9A%E8%BF%87%E7%89%B9%E6%AE%8A%E6%88%90%E5%83%8F%E6%8A%80%E6%9C%AF%E4%BB%A5%E5%8F%8A%E4%BA%BA%E5%B7%A5%E6%99%BA%E8%83%BD%E8%BE%85%E5%8A%A9%E8%BD%AF%E4%BB%B6%E8%A7%A3%E5%86%B3%E6%96%B9%E6%A1%88%EF%BC%8C%E5%8F%AF%E4%BB%A5%E5%AE%9E%E7%8E%B0%E4%B8%80%E7%A7%8D%E5%85%A8%E6%96%B0%E7%9A%84%E5%BF%83%E8%84%8F%E5%BD%B1%E5%83%8F%E7%94%9F%E6%88%90%E6%96%B9%E5%BC%8F%E3%80%82%E4%BB%8E%E8%80%8C%E5%88%86%E6%9E%90%E5%86%A0%E7%8A%B6%E5%8A%A8%E8%84%89%E5%A3%81%E4%B8%8A%E7%9A%84%E6%96%91%E5%9D%97%E7%BB%84%E6%88%90%EF%BC%8C%E6%9C%89%E5%8A%A9%E4%BA%8E%E8%BF%9B%E8%A1%8C%E4%B8%AA%E4%BD%93%E9%A3%8E%E9%99%A9%E8%AF%84%E4%BC%B0%E5%B9%B6%E6%8E%A2%E7%B4%A2%E9%A2%84%E9%98%B2%E6%B2%BB%E7%96%97%E6%96%B9%E6%A1%88%EF%BC%8C%E2%80%9D%E8%8E%B1%E5%A7%86%E5%BA%93%E5%B0%94%E5%8C%BB%E7%94%9F%E6%8C%87%E5%87%BA%E3%80%82%3C/p%3E%0A%20%0A%20%3CP%3E%3Cb%20%3E%20%E8%AF%8A%E6%96%AD%E4%B8%8E%E4%BB%8B%E5%85%A5%E6%94%BE%E5%B0%84%E5%AD%A6%E5%8F%8A%E7%A5%9E%E7%BB%8F%E6%94%BE%E5%B0%84%E5%AD%A6%20%3C/b%3E%3C/P%20%3E%0A%20%0A%20%3CP%20%3E%20%E8%B4%9F%E8%B4%A3%E7%A1%AE%E4%BF%9D%20RH%C3%96N-KLINIKUM%20Campus%20Bad%20Neustadt%20%E6%89%80%E6%9C%89%E4%B8%B4%E5%BA%8A%E4%B8%93%E4%B8%9A%E9%A2%86%E5%9F%9F%E5%8F%8A%E4%B8%AD%E5%A4%AE%E6%80%A5%E6%95%91%E5%AE%A4%20%E7%9A%84%20%E6%94%BE%E5%B0%84%20%E5%AD%A6%20%E5%92%8C%20%E7%A5%9E%20%E7%BB%8F%20%E6%94%BE%20%E5%B0%84%20%E5%AD%A6%20%E6%9C%8D%E5%8A%A1%20%E3%80%82%20%E5%AE%83%E7%94%B1%20PD%20Dr.%20med.%20Lukas%20Lehmkuhl%20%28Diagnostik%29%20%E5%92%8C%20Prof.%20Dr.%20med.%20Andr%C3%A9%20Kemmling%20%28Intervention%29%20%E4%B8%BB%E6%8C%81%20%E3%80%82%20%E6%94%BE%20%E5%B0%84%20%E5%AD%A6%20%E8%A2%AB%20%E5%BE%B7%20%E5%9B%BD%20X%20%E5%85%89%20%E5%8D%8F%20%E4%BC%9A%20%28DRG%29%20%E8%AE%A4%E8%AF%81%20%E4%B8%BA%20%E5%BF%83%20%E8%A1%80%20%E7%AE%A1%20%E6%88%90%20%E5%83%8F%20%E4%B8%AD%20%E5%BF%83%20%E3%80%82%20%E6%AF%8F%20%E5%B9%B4%20%E5%9C%A8%20%E6%AD%A4%20%E5%9C%B0%20%E6%89%A7%20%E8%A1%8C%20%E5%A4%A7%E7%BA%A6%2050%2C000%20%E6%AC%A1%20X%20%E5%85%89%20%E6%A3%80%20%E6%9F%A5%20%E3%80%8118%2C000%20%E6%AC%A1%20CT%20%E6%A3%80%E6%9F%A5%20%E5%92%8C7%2C000%20%E6%AC%A1%20MRI%20%E6%A3%80%E6%9F%A5%20%E3%80%82%20%3C/%20P%20%3E%0A%0A%3CP%20%3E%3C%20b%20%3E%20RH%20%C3%96%20N%20-%20K%20LIN%20IK%20UM%20AG%20%3C/%20b%20%3E%3C/%20P%20%3E%0A%0A%3CP%20%3E%20%E6%98%AF%20%E5%BE%B7%20%E5%9B%BD%20%E6%9C%80%E5%A4%A7%20%E7%9A%84%20%E5%8C%BB%20%E7%96%97%20%E6%9C%8D%E5%8A%A1%20%E6%8F%90%E4%BE%9B%20%E5%95%86%20%E4%B9%8B%20%E4%B8%80%20%E3%80%82%20%E5%90%84%20%E5%8C%BB%20%E9%99%A2%20%E6%8F%90%E4%BE%9B%20%E4%BC%98%20%E7%A7%80%20%E7%9A%84%20%E5%8C%BB%20%E7%96%97%20%EF%BC%8C%20%E4%B8%8E%20%E5%A4%A7%20%E5%AD%A6%20%E5%92%8C%20%E7%A7%91%E7%A0%94%20%E5%8D%95%20%E4%BD%8D%20%E7%B4%A7%20%E5%AF%86%20%E7%9B%B8%20%E8%BF%9E%20%E3%80%82%20%E5%9C%A8%20%E5%B7%B4%20%E5%BE%B7%20%E6%96%B0%20%E5%8A%B3%20%E5%A1%94%20%E6%A0%A1%20%E5%8C%BA%20%E3%80%81%20%E6%B3%95%20%E5%85%B0%20%E5%85%8B%20%E7%A6%8F%20%EF%BC%88%20%E5%A5%A5%20%E5%BE%B7%20%EF%BC%89%20%E5%8C%BB%20%E9%99%A2%20%E3%80%81%20%E5%90%89%20%E6%A0%B9%20%E5%A4%A7%20%E5%AD%A6%20%E9%99%A2%20%E6%A0%A1%20%EF%BC%88%20UKGM%20%EF%BC%89%20%E5%92%8C%20%E9%A9%AC%20%E5%B0%94%20%E4%BC%AF%20%E6%A0%BC%20%E5%A4%A7%20%E5%AD%B8%20%E9%99%A2%20%E6%A0%A1%20%E7%AD%89%20%E4%BA%94%20%E4%B8%AA%20%E5%9C%B0%20%E7%82%B9%20%EF%BC%8C%20%E6%AF%8F%20%E5%B9%B4%20%E6%8E%A5%E5%BE%85%20%E5%A4%A7%E7%BA%A6913%2C000%20%E5%90%8D%20%E6%82%A3%20%E8%80%85%E3%80%82%E6%9C%89%20%E8%B6%85%E8%BF%8718%2C700%20%E5%90%8D%20%E5%91%98%E5%B7%A5%20%E5%9C%A8%20%E5%85%AC%E5%8F%B8%20%E5%B7%A5%E4%BD%9C%20.%20%E5%88%9B%20%E6%96%B0%20%E7%9A%84%20RH%20%C3%96%20N%20-%20C%20AM%20PU%20S%20%E6%A6%82%20%E5%BF%B5%20%E4%B8%BA%20%E5%86%9C%20%E6%9D%91%20%E5%9C%B0%20%E5%8C%BA%20%E6%8F%90%E4%BE%9B%20%E8%B7%A8%20%E9%83%A8%20%E9%97%A8%20%E7%9A%84%20%E5%81%A5%E5%BA%B7%20%E6%9C%8D%E5%8A%A1%20%2C%20%E6%8C%81%E7%BB%AD%20%E6%8E%A8%20%E5%8A%A8%20%E4%BC%81%E4%B8%9A%20%E6%95%B0%20%E5%AD%97%20%E5%8C%96%20%E8%BD%AC%E5%9E%8B%20%2C%20%E4%B8%8E%20Asklepios%20%E5%BB%BA%E7%AB%8B%20%E6%88%98%E7%95%A5%20%E5%90%88%E4%BD%9C%E4%BC%99%E4%BC%B4%E5%85%B3%E7%B3%BB%20%E6%98%AF%20%E4%BC%81%E4%B8%9A%E6%88%98%E7%95%A5%E7%9A%84%E9%87%8D%E8%A6%81%E6%94%AF%E6%9F%B1%20.%20RH%20%C3%96%20N%20-%20K%20LIN%20IK%20UM%20AG%20%E6%98%AF%E4%B8%80%E5%AE%B6%E7%8B%AC%E7%AB%8B%E4%BC%81%E4%B8%9A%20%EF%BC%8C%20%E9%9A%B6%E5%B1%9E%E4%BA%8E%20Asklepios%20Kliniken%20GmbH%20%26%20Co.KGaA%20.%20www.rhoen-klinikum-ag.com%20%3C/%20P%20%3E%0A%0A%3CP%20%3E%20%E6%96%B0%E9%97%BB%20%E8%81%94%E7%B3%BB%20%E4%BA%BA%20%EF%BC%9A%20%3C/%20P%20%3E%0A%20%0A%3CP%20%3E%20RH%20%C3%96%20N%20-%20K%20LIN%20IK%20UM%20AG%20%7C%20%E4%BC%81%E4%B8%9A%E4%BC%A0%E6%92%AD%E4%B8%8E%E8%90%A5%E9%94%80%20%3C%20br%20/%3E%20%E6%B5%B7%E5%85%8B%20%C2%B7%20%E5%A5%A5%E8%B5%AB%E6%9B%BC%20%7C%20T%20%2B49%209771%2065-12130%20%7C%20heike.ochmann%40rhoen-klinikum-ag.com%20%3C%20br%20/%3E%3C%20br%20/%3E%20RH%20%C3%96%20N%20-%20K%20LIN%20IK%20UM%20Campus%20Bad%20Neustadt%20%7C%20%E9%80%9A%E8%AE%AF%20%3C%20br%20/%3E%20%E5%8D%A1%E7%89%B9%E7%90%B3%20%C2%B7%20%E8%88%92%E5%AF%86%20%E7%89%B9%20%7C%20T%20%2B49%209771%2066-26100%20%7C%20kommunikation%40campus-nes.de%20%3C/%20P%20%3E%0A

%60%60%60html%0A%3Cimg%20height%3D%27540%27%20with%3D%27720%27%20src%3D%27https%3A//cache.pressmailing.net/thumbnail/story_big/e41cedc5-88c9-4af8-beec-f91653970d16/revolution-im-gesundheitswesen-von-ki-und-einem-zugang-zur-besten-versorgung-das-war-der-roche-summe%27%20srcset%3D%27https%3A//cache.pressmailing.net/thumbnail/story_big/e41cedc5-88c9-4af8-beec-f91653970d16/revolution-im-gesundheitswesen-von-ki-und-einem-zugang-zur-besten-versorgung-das-war-der-roche-summe%20710w%2C%20https%3A//cache.pressmailing.net/thumbnail/story_small/e41cedc5-88c9-4af8-beec-f91653970d16/revolution-im-healthcare-von-ai-und-einem-access-to-best-care-das-war-the-roche-summer-summit%20532w%27%20sizes%3D%27%28min-width%3A%201360px%29%20720px%2C%20%28min-width%3A%201000px%29%2054.71vw%2C%20%28min-width%3A%20780px%29%20calc%2866.5vw%20-%2072px%29%2C%20calc%28100vw%20-%2048px%29%27%20alt%3D%27Revolution%20im%20Gesundheitswesen%3F%20Von%20KI%20und%20einem%20Zugang%20zur%20besten%20Versorgung%3A%20das%20war%20der%20Roche%20Summer%20Summit%202025%27%20class%3D%27single%27/%3E%0A%0A%3Cp%3E%3Cb%3EDie%20klinische%20Forschung%20in%20Deutschland%20steht%20vor%20Herausforderungen%20%E2%80%93%20und%20damit%20auch%20die%20medizinische%20Zukunft%20des%20Landes.%20Auf%20dem%20Roche%20Summer%20Summit%202025%20er%C3%B6rterten%20Fachleute%20aus%20den%20Bereichen%20Forschung%2C%20Industrie%20und%20Patientenorganisationen%20Strategien%20zur%20St%C3%A4rkung%20des%20Studienstandorts%20Deutschland.%20Jede%20klinische%20Studie%20er%C3%B6ffnet%20den%20Patient%3Ainnen%20Zugang%20zu%20potenziellen%20Therapieans%C3%A4tzen%20und%20Technologien%2C%20die%20au%C3%9Ferhalb%20von%20Studien%20m%C3%B6glicherweise%20nicht%20verf%C3%BCgbar%20sind%20%E2%80%93%20zudem%20erm%C3%B6glicht%20sie%20%C3%84rzt%3Ainnen%20fr%C3%BChzeitige%20Erfahrungen%20mit%20innovativen%20Methoden.%3C/b%3E%3C/p%3E%0A%0A%3Cp%3EF%C3%BCr%20die%20Medizin%20der%20Zukunft%20sind%20zwei%20Aspekte%20entscheidend%3A%20eine%20starke%20Stimme%20der%20Patient%3Ainnen%20sowie%20die%20transformative%20Kraft%20k%C3%BCnstlicher%20Intelligenz%20%28KI%29.%20Was%20geschieht%2C%20wenn%20wir%20diese%20beiden%20Elemente%20zusammenbringen%3F%20Um%20genau%20diese%20Frage%20zu%20er%C3%B6rtern%2C%20trafen%20sich%20%C3%BCber%20hundert%20Patient%3Ainnen%20sowie%20Vertreter%3Ainnen%20von%20Patientenorganisationen%2C%20%C3%84rzt%3Ainnen%20und%20Forschende%20zum%20vierten%20Mal%20beim%20Summer%20Summit%20in%20Grenzach-Wyhlen.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EAnregungen%20f%C3%BCr%20den%20Studienstandort%20Deutschland%3C/b%3E%3C/p%3E%0A%0A%3Cp%3EDie%20Gespr%C3%A4che%20konzentrierten%20sich%20darauf%2C%20wie%20man%20die%20Rahmenbedingungen%20f%C3%BCr%20klinische%20Studien%20in%20Deutschland%20verbessern%20kann.%20Die%20Forderung%20der%20anwesenden%20Patient%3Ainnen%20war%20klar%3A%20mehr%20Transparenz%20sowie%20einfachere%20Informationen%20und%20Zug%C3%A4nge%20zu%20klinischen%20Studien.%20Dr.%20Daniel%20Steiners%20von%20Roche%20Pharma%20AG%20betonte%3A%20%22Deutschland%20l%C3%A4uft%20Gefahr%2C%20im%20Bereich%20der%20klinischen%20Forschung%20zur%C3%BCckzufallen.%20Komplexe%20Genehmigungsverfahren%20und%20unzureichende%20digitale%20Infrastruktur%20bremsen%20uns%20aus%3B%20w%C3%A4hrend%20andere%20L%C3%A4nder%20schneller%20agieren%20k%C3%B6nnen.%22%20Er%20forderte%20pragmatische%20bundesweit%20einheitliche%20Regelungen%20sowie%20eine%20konsequente%20Digitalisierung%20aller%20Prozesse%20als%20Schl%C3%BCssel%20zur%20Sicherstellung%20neuer%20Therapieoptionen%20f%C3%BCr%20alle%20Betroffenen.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EK%C3%BCnstliche%20Intelligenz%20als%20Bindeglied%20zwischen%20Forschung%20und%20Alltag%3C/b%3E%3C/p%3E%0A%0A%3Cp%3EWie%20k%C3%B6nnen%20aktuelle%20Entwicklungen%20im%20Bereich%20K%C3%BCnstlicher%20Intelligenz%20dazu%20beitragen%2C%20dass%20Patient%3Ainnen%20gemeinsam%20mit%20ihrem%20Behandlungsteam%20fundierte%20Entscheidungen%20%C3%BCber%20Therapien%20treffen%3F%20Diese%20Fragen%20wurden%20in%20mehreren%20Diskussionsrunden%20behandelt.%3C/p%3E%0A%0A%3Cp%3EBasis%20dieser%20Diskussion%20war%20das%20k%C3%BCrzlich%20ver%C3%B6ffentlichte%20Whitepaper%20%22Mit%20KI%20zur%20gemeinsamen%20Entscheidungsfindung%20in%20der%20Medizin%22%2C%20das%20durch%20enge%20Zusammenarbeit%20zwischen%20Mitgliedern%20des%20neu%20gegr%C3%BCndeten%20Patientenrates%20bei%20Roche%20Pharma%20AG%20sowie%20Experten%20aus%20dem%20Gesundheitssektor%20entstand.%20Dr.%20Alexandra%20Widmer%20hob%20hervor%2C%20dass%20heutige%20Therapieoptionen%20individuell%20auf%20jede%3An%20Patient%3Ain%20abgestimmt%20werden%20sollten%3B%20%22K%C3%BCnstliche%20Intelligenz%20kann%20helfen%20komplexe%20Behandlungsalternativen%20verst%C3%A4ndlich%20darzustellen.%22%20Der%20Hauptautor%20Dr.%20Sven%20Jungmann%20erg%C3%A4nzte%20dies%20mit%20dem%20Hinweis%20darauf%2Cdass%20KI%20%C3%84rzt%3Ainnen%20bei%20ihrer%20anspruchsvollen%20Arbeit%20unterst%C3%BCtzen%20k%C3%B6nnte%20%E2%80%93%20was%20wiederum%20das%20Vertrauen%20seitens%20der%20Patient%3Ainnen%20st%C3%A4rken%20k%C3%B6nnte.%3C/p%3E%0A%0A%3Cp%3EDario%20Madani%20vom%20PRO%20RETINA%20Deutschland%20e.V.%2C%20selbst%20vollblind%20geworden%20ist%20dank%20KI%20nun%20in%20der%20Lage%20komplexe%20digitale%20Inhalte%20besser%20zug%C3%A4nglich%20gemacht%20zu%20bekommen%3B%20dieses%20Beispiel%20verdeutlicht%20eindrucksvoll%20wie%20KI%20informierte%20Entscheidungen%20f%C3%B6rdern%20kann.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EBlick%20nach%20vorn%3A%20Aktive%20Partnerschaft%20mit%20den%20Patient%3Ainnen%3C/b%3E%3C/p%3E%0A%20%0A%3Cp%3EDer%20Summer%20Summit%20hat%20gezeigt%20%3A%20Ob%20es%20um%20schnellere%20Abl%C3%A4ufe%20bei%20klinischen%20Studien%20oder%20um%20gemeinsame%20Entscheidungen%20unter%20Einbeziehung%20von%20KI%20geht%20%E2%80%93%20entscheidend%20ist%20eine%20partnerschaftliche%20Zusammenarbeit%20auf%20Augenh%C3%B6he%20.%20Wenn%20die%20Perspektiven%20von%20patientinnen%20nicht%20nur%20geh%C3%B6rt%20%2C%20sondern%20aktiv%20integriert%20werden%20%2C%20entsteht%20ein%20Mehrwert%20f%C3%BCr%20alle%20Beteiligten%20.%20Inwiefern%20wird%20K%C3%BCnstliche%20Intelligenz%20tats%C3%A4chlich%20revolution%C3%A4r%20sein%20%3F%20In%20jedem%20Fall%20ver%C3%A4ndert%20sie%20bereits%20jetzt%20unsere%20Kommunikation%20zwischen%20Arzt%20%3Ain%20%26%20patient%20%3Ain%20.%20%3C/p%3E%0A%20%0A%20%3Cp%3EKostenloses%20Downloadangebot%20des%20KI-Wei%C3%9Fbuchs%20finden%20Sie%20hier%20%3A%20www.patientenimfokus.de/ki/%3C/%20p%3E%0A%20%0A%20%3C%20p%3EBildermaterial%20steht%20unter%20folgendem%20Link%20bereit%20%3A%20https%3A//roche.picturepark.com/s/cELb9cF4%20%3C/%20p%3E%0A%20%0A%20%3C%20p%20%3ERoche%20-%20Unternehmensinformationen%20%3C/%20p%3E%0A%20%20%0A%20%3C%20p%20%3EPressekontakt%20%3A%3C/%20p%20%3E%0A%20%20%0A%20%3C%20p%20%3EAnja%20Peter%3Cbr%20/%3EKommunikation%20%26%20%C3%96ffentlichkeitsarbeit%3Cbr%20/%3ERoche%20Pharma%20AG%3Cbr%20/%3EEmil-Barell-Stra%C3%9Fe1%3Cbr%20/%3E79639%20Grenzach-Wyhlen%3Cbr%20/%3Eanja.peter%40roche.com%3Cbr/%3ETel.%3A07624%20/14%20-2723%20%3C/%20P%20%3E%0A%60%60%60

%3Cp%3E%3Ci%3EDie%20Mikrona%20Group%20AG%2C%20ein%20f%C3%BChrender%20Anbieter%20von%20L%C3%B6sungen%20in%20der%20Kieferorthop%C3%A4die%20und%20digitalen%20Zahnmedizin%20aus%20der%20Schweiz%2C%20hat%20die%20FTC%20Frey%20Trading%20%26%20Consulting%20S%C3%A0rl%20sowie%20die%20dazugeh%C3%B6rige%20Trainingsplattform%20MYDENTALEXPERT%20S%C3%A0rl%20%C3%BCbernommen.%20Die%20Mikrona%20Group%20ist%20Teil%20der%20Healthcare%20Holding%20Schweiz%20AG%2C%20die%20unter%20dem%20Management%20von%20Winterberg%20Advisory%20und%20KKA%20Partners%20steht.%3C/i%3E%3C/p%3E%0A%0A%3Cp%3EDie%20Healthcare%20Holding%20Schweiz%20AG%20hat%20durch%20ihre%20Tochtergesellschaft%20Mikrona%20Group%20AG%20den%20Erwerb%20der%20FTC%20Frey%20Trading%20%26%20Consulting%20S%C3%A0rl%20in%20Crans-pr%C3%A8s-C%C3%A9ligny%20sowie%20der%20Online-Plattform%20MyDentalExpert%20S%C3%A0rl%20in%20St-Cergue%20im%20Waadtland%20abgeschlossen.%20Bernhard%20Frey%2C%20ein%20europaweit%20anerkannter%20Spezialist%20f%C3%BCr%20Wurzelkanalbehandlungen%20und%20Zahnerhaltung%2C%20bleibt%20weiterhin%20als%20Gesch%C3%A4ftsf%C3%BChrer%20aktiv%20und%20beteiligt%20sich%20an%20den%20Unternehmen.%20Seit%20rund%2020%20Jahren%20ist%20FTC%20Dental%20auf%20Endodontie%20spezialisiert%20und%20bietet%20eine%20umfassende%20Produktpalette%20f%C3%BCr%20Wurzelkanalbehandlungen%20an%3A%20Dazu%20geh%C3%B6ren%20Instrumente%20zur%20Aufbereitung%2C%20Biokeramiken%2C%20Obturationsger%C3%A4te%20sowie%20Mikroskope%20und%20Lupenbrillen.%20Die%20praxisorientierten%20Schulungen%20von%20FTC%20Dental%20werden%20sowohl%20digital%20als%20auch%20hybrid%20oder%20praktisch%20durchgef%C3%BChrt.%3C/p%3E%0A%0A%3Cp%3EFabio%20Fagagnini%2C%20CEO%20von%20Healthcare%20Holding%20Schweiz%20und%20Mikrona%20Group%20erkl%C3%A4rt%3A%20%E2%80%9EFTC%20Dental%20ist%20eine%20Marke%20mit%20einem%20hohen%20Bekanntheitsgrad%20unter%20Zahn%C3%A4rzten.%20Ihr%20Konzept%20verbindet%20Produkte%20mit%20praxisnahen%20Schulungen%20ideal%20mit%20unserem%20Portfolio%20spezialisierter%20Anbieter%20im%20Bereich%20Kieferorthop%C3%A4die%20und%20Zahnmedizin.%20Dadurch%20k%C3%B6nnen%20wir%20einen%20Beratungs-%20und%20Expertenstandard%20bieten%2C%20den%20andere%20nicht%20erreichen%20k%C3%B6nnen%20%E2%80%93%20das%20verschafft%20uns%20einen%20entscheidenden%20Vorteil%20bei%20diesen%20erkl%C3%A4rungsbed%C3%BCrftigen%20Produkten.%22%3C/p%3E%0A%0A%3Cp%3EBernhard%20Frey%20erg%C3%A4nzt%3A%20%E2%80%9EIch%20bin%20sehr%20erfreut%20dar%C3%BCber%2C%20dass%20wir%20mit%20Mikrona%20Group%20und%20Healthcare%20Holding%20Schweiz%20den%20passenden%20Partner%20f%C3%BCr%20unser%20Wachstum%20gefunden%20haben.%20Der%20Schweizer%20Markt%20f%C3%BCr%20Zahnmedizin%20steht%20ebenfalls%20unter%20Kostendruck%3B%20es%20besteht%20Bedarf%20nach%20qualitativ%20hochwertigen%20Alternativen%20zu%20deutlich%20g%C3%BCnstigeren%20Preisen%20im%20Bereich%20Endodontie%20%E2%80%93%20dies%20kommt%20sowohl%20Zahn%C3%A4rzten%20als%20auch%20Patienten%20zugute.%20Viele%20Zahnarztpraxen%20sowie%20Universit%C3%A4ten%20nutzen%20bereits%20unsere%20Produkte%3B%20wir%20freuen%20uns%20%C3%BCber%20jede%20Anfrage%20zu%20Produkttests%20oder%20Weiterbildungen.%22%20%3C/p%3E%0A%0A%3Cp%3E%3Cb%3E%C3%9Cber%20FTC%20Frey%20Trading%20%26%20Consulting%20S%C3%A0rl%20sowie%20MyDentalExpert%20S%C3%A0rl%3C/b%3E%3C/p%3E%0A%3Cp%3EFTC%20Frey%20Trading%20%26%20Consulting%20S%C3%A0rl%20mit%20Sitz%20in%20Crans-pr%C3%A8s-C%C3%A9ligny%20ist%20seit%202005%20auf%20hochwertige%20Endodontie-Produkte%20spezialisiert%3B%20sie%20zeichnen%20sich%20durch%20schnellen%20Service%20sowie%20ein%20umfangreiches%20Fortbildungsangebot%20aus.%20Unter%20dem%20Markennamen%20FTC%20Dental%20bietet%20das%20Unternehmen%20innovative%20Instrumente%20samt%20Zubeh%C3%B6r%20ebenso%20wie%20Praxisschulungen%20an.%20MyDentalExpert%20S%C3%A0rl%20wurde%202022%20gegr%C3%BCndet%3B%20sie%20erweitert%20das%20Angebot%20um%20eine%20digitale%20Plattform%20f%C3%BCr%20praxisnahe%20Online-%20sowie%20Hybridkurse%20f%C3%BCr%20Zahn%C3%A4rzte.%3C/p%3E%0A%20%20%0A%3Cp%3EBeide%20Firmen%20stehen%20synonym%20f%C3%BCr%20Schweizer%20Qualit%C3%A4t%20gepaart%20mit%20Kundenn%C3%A4he%3B%20ihr%20Ziel%20ist%20es%20stets%20darin%20zu%20bestehen%2C%20Fachkr%C3%A4fte%20optimal%20zu%20unterst%C3%BCtzen.%20Gegr%C3%BCndet%20von%20Bernhard%20Frey%20haben%20sich%20sowohl%20FTC%20als%20auch%20MyDentalExpert%20als%20vertrauensw%C3%BCrdige%20Partner%20moderner%20Zahnheilkunde%20etabliert.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3E%C3%9Cber%20die%20Mikrona%20Group%20AG%3C/b%3E%3C/p%3E%0A%3Cp%3EMikrona%20Group%20AG%20hat%20ihren%20Sitz%20in%20Schlieren%20%28Schweiz%29und%20gilt%20seit%201959%20als%20f%C3%BChrender%20Anbieter%20innovativer%20L%C3%B6sungen%20speziell%20f%C3%BCr%20Kieferorthop%C3%A4den%20wie%20auch%20Dentisten%20.%20Die%20Gruppe%20vereint%20Marken%20wie%20%3Cb%3EMikrona%3C/b%3E%2C%20%3Cb%3EOrtho%20Walker%20%3C/b%3E%2Cund%3Cb%3EDental%20Axess%20%3C/b%3E.%20Sie%20steht%20zudem%20stellvertretend%20fu%CC%88r%20Schweizer%20Qualita%CC%88t%20%2Ctechnologische%20Kompetenz%20%2Csowie%20enge%20Kundenbindung%20.Mikronas%20hochmodernen%20Behandlungseinheiten%20genie%C3%9Fen%20europaweit%20Anerkennung%20aufgrund%20ihrer%20Innovationskraft%20%3B%20Ortho%20Walker%20vertreibt%20hochwertige%20kieferorthop%C3%A4dische%20Produkte%20nahezu%20aller%20renommierten%20Herstellermarken%20%E2%80%93%20damit%20nimmt%20man%20unangefochten%20Platz%20eins%20auf%20dem%20Markt%20innerhalb%20der%20Schweiz%20ein.Dental%20Axess%20erg%C3%A4nzt%20schlie%C3%9Flich%20das%20Portfolio%20um%20digitale%20L%C3%B6sungen%20fu%CC%88r%20Zahntechniker%2CZahn%C3%A4rzte%2CKFO-Praxen.Mit%20einem%20integrierten%20Ansatz%20entlang%20s%C3%A4mtlicher%20Wertsch%C3%B6pfungsketten%20positioniert%20sich%20diese%20Gruppe%20erfolgreich%20strategisch%20gegen%C3%BCber%20modernen%2Czukunftsorientierten%20Praxismodellen.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3E%C3%9Cber%20die%20Healthcare%20Holding%20Schweiz%20AG%3C/b%3E%3C/p%3E%0A%3Cp%3EThe%20HealthCare%20Holdings%20Switzerland%20is%20a%20buy-build-and-technologize%20platform%20that%20has%20established%20itself%20as%20a%20leading%20provider%20of%20medical%20technology%20products%20and%20services%20within%20Switzerland.The%20company%20is%20headquartered%20at%20Baar%20and%20pursues%20ambitious%20growth%20strategies%20primarily%20through%20acquisitions%20related%20to%20succession%20arrangements%20as%20well%20as%20partnerships%20alongside%20organic%20growth%20initiatives.The%20group%20prioritizes%20high%20standards%20concerning%20innovation%20while%20ensuring%20customer%20satisfaction%20throughout%20its%20operations%20by%20implementing%20advanced%20technologies%20aimed%20at%20optimizing%20business%20processes%20effectively.As%20market%20leaders%20they%20set%20new%20benchmarks%20across%20industries%20offering%20employees%20attractive%20career%20development%20opportunities.Fabio%20Fagagnini%20currently%20serves%20as%20CEO%20since%20early%20twenty-three%20years%20managing%20this%20dynamic%20entrepreneurial%20community%20comprised%20entirely%20of%20committed%20partners%20invested%20into%20their%20firm%E2%80%99s%20success%21%3C/P%20%3E%0A%0A%3CP%20%3E%3CB%20%3E%20%C3%9Cber%20KKA%20Partners%20%3C/B%20%3E%3C/P%20%3E%0A%3CP%20%3EKKA%20Partners%20wurde%20zwei-tausend-und-achtzehn%20gegr%C3%BCndet%20%3Bsie%20sind%20ans%C3%A4ssig%20innerhalb%20Berlins.Sie%20fungieren%20haupts%C3%A4chlichals%20Beteiligungsgesellschaftin%20mittelst%C3%A4ndischen%20Unternehmen%20Deutschlands%20%2C%C3%96sterreichs%2CsowiederSchweiz.Das%20Gr%C3%BCndungsteam%20bringt%20mehrj%C3%A4hrige%20Erfahrungmit%20mittelst%C3%A4ndischen%20Firmenmitund%20unterst%C3%BCtzt%20derenManagementbei%20weiteren%20Entwicklungen.KKA%20verfolgt%20dabei%20ihren%20eigens%20entwickelten%20Ansatz%20namens%20Technology%20Enabled%20Transformation%20um%20nachhaltig%20wettbewerbsf%C3%A4higerzu%20bleiben%21%3C%20/%20P%20%3E%0A%0A%3CP%20%3E%3CB%20%3E%20%C3%9Cber%20Winterberg%20Advisory%20GmbHundWinterbergGroupAG%20%3C/B%20%3E%3C/P%20%3E%0A%3CP%20%3EDieWinterbergGroupAGhatihrenSitzinZugundsiehtsichalsunabh%C3%A4ngigesFamilyOfficef%C3%BCrGr%C3%BCnder.IhreInvestitionenkonzentrieren%20sichhaupts%C3%A4lichaufKMUsimdeutschsprachigenRaum.SelektivwerdenauchStartupsoderImmobilieninvestiert.WinterbergAdvisoryGmbHistGeneralPartnerundFondsmanagerreguliertdurchdeutscheBaFin.SowohlPrivateEquityfondswurdenaufgelegtunteranderemauchWinterbergsInvestmentVIII%26IX%20investiertenbereitsindieHealthcareHoldingSchweizAG.ZweiPartnerExecutiveDirectorsFabianKr%C3%B6herFlorianBrickensteinf%C3%BChrenhierbeiHealthcareHoldingSchweiz%C3%BCberderenVerwaltungsrat.%3C%20/%20P%20%3E%0A%0A%3CP%20%3EF%C3%BCr%20Presseanfragen%20wenden%20Sie%20sich%20bitte%20an%20presse%40healthcare-holding.ch%3C/P%20%3E%0A%3CP%20%3E%3CI%20Hinweis%20f%26uuml%3Br%20Redakteure%20%3ABitte%20nenneHealthcareHoldingSchweizAGbeiallenVerweisenaufbereitgestellteZitateinformationen%21%3C/I%20%3E%3C/P%20%3E%0A%20%0A%20%3CP%20%3EWeitere%20Informationen%20%C3%BCberFTC-DentalfindenSieunterwww.ftcdental.ch%20www.mydentalexpert.ch%20%21%3C%20/%20P%20%3E%0A%0A%20%3CP%20%3EWeitere%20Informationen%C3%BCberHealthcare-Holding-SchweizAGfindenSieunterwww.healthcare-holding.ch%20%21%3C%20/%20P%20%3E%0A%0A%20%3CP%20%3EZus%C3%A4tzlicheDetailszuPortfoliofirmenvonHealthCareHoldingsindverf%C3%BCgbarunter%3Awww.senectovia.ch%2Cwww.winthermedical.ch%2Cwww.mikronacom%2Cwww.dentaxess.com%2C%3C%20br%20/%3E%20www.effectum-chrep.com%2Cwww.schaublin-medica%2Cch/www.cdpswiss.com/www.aestheticbedarfch/%20www.inomedicalsolutions/ch/%3Cbr%20/%3E%3C/%20p%20%3E%0A%20%0A%20%3CP%20%3E%3C%20B%3EZudem%20gibt%20es%20weitereInformationenzuKKAPartnersfindensiedunderwww.kkapartnerscom/winterberadvisorygmbhunterwwwwinterberggroupcom%21%3C%20/%20B%20%3E%3C/%20P%20%3E%0A%20%0A%20%3C%20p%20class%3D%22last%22%3EDiese%20Pressemitteilung%20wirdvonWinterbergerAdvisoryGmbHinAuftragderHealthCare-Holdingschweizzugestellt.%3C%20/%20p%20%3E%0A%0A%20%20

%60%60%60html%0A%3Cul%3E%0A%3Cli%3E%20Takeda%20plant%2C%20den%20Hauptsitz%20der%20Takeda%20GmbH%20bis%20Ende%202028%20von%20Konstanz%20nach%20Berlin%20zu%20verlegen.%20%3C/li%3E%0A%3Cli%3E%20Zuk%C3%BCnftiger%20Schwerpunkt%20liegt%20auf%20drei%20Standorten%3A%20Berlin%20sowie%20den%20Produktionsst%C3%A4tten%20in%20Oranienburg%20und%20Singen.%20%3C/li%3E%0A%3Cli%3E%20Die%20Mitarbeiter%20in%20Konstanz%20wurden%20heute%20%C3%BCber%20die%20bevorstehenden%20%C3%84nderungen%20informiert.%20%3C/li%3E%0A%3C/ul%3E%0A%0A%3Cp%3E%20Das%20renommierte%20Pharmaunternehmen%20Takeda%20hat%20angek%C3%BCndigt%2C%20dass%20der%20Sitz%20seiner%20deutschen%20Tochtergesellschaft%2C%20der%20Takeda%20GmbH%2C%20bis%20Ende%202028%20von%20Konstanz%20nach%20Berlin%20verlegt%20wird.%20In%20Berlin%20werden%20bereits%20jetzt%20zentrale%20Aufgaben%20f%C3%BCr%20den%20Vertrieb%20in%20Deutschland%20wahrgenommen.%20Mit%20dieser%20Entscheidung%20zur%20Ansiedlung%20der%20Takeda%20GmbH%20in%20der%20Hauptstadt%20verst%C3%A4rkt%20das%20Unternehmen%20seine%20Pr%C3%A4senz%20vor%20Ort%20und%20konzentriert%20sich%20k%C3%BCnftig%20auf%20drei%20Schl%C3%BCsselstandorte%3A%20Berlin%2C%20Oranienburg%20und%20Singen.%20Die%20modernen%20Produktionsst%C3%A4tten%20in%20Singen%20und%20Oranienburg%20bleiben%20unverzichtbare%20Bestandteile%20des%20Unternehmens%20und%20heben%20die%20Bedeutung%20Deutschlands%20als%20wichtigen%20Standort%20f%C3%BCr%20die%20Industrie%20hervor.%3C/p%3E%0A%0A%3Cp%3E%20%22Die%20Verlagerung%20unserer%20Unternehmenszentrale%20nach%20Berlin%20ist%20ein%20klares%20Bekenntnis%20zu%20Deutschland%20als%20dem%20viertgr%C3%B6%C3%9Ften%20Markt%20von%20Takeda%22%2C%20erkl%C3%A4rte%20Dr.%20Ingeborg%20R.%20Borgheim%2C%20Gesch%C3%A4ftsf%C3%BChrerin%20von%20Takeda%20Deutschland.%20%22Wir%20erweitern%20unsere%20Pr%C3%A4senz%20in%20Berlin%20zus%C3%A4tzlich%20zu%20unseren%20beiden%20globalen%20Produktionsstandorten%20hierzulande.%22%20%3C/p%3E%0A%0A%3Cp%3E%20Der%20Umzug%20des%20Hauptsitzes%20soll%20bis%20zum%20Jahresende%202028%20abgeschlossen%20sein.%20Der%20Standort%20Konstanz%2C%20historisch%20gesehen%20das%20Zentrum%20der%20Takeda%20GmbH%20sowie%20Hauptsitz%20von%20Takeda%20Deutschland%2C%20wird%20bis%20Ende%202028%20geschlossen%20werden.%20Rund%2060%20Mitarbeiter%20am%20Standort%20wurden%20bereits%20%C3%BCber%20diese%20Pl%C3%A4ne%20informiert.%3C/p%3E%0A%0A%3Cp%3E%20%22Wir%20sind%20uns%20bewusst%2C%20dass%20dies%20eine%20erhebliche%20Ver%C3%A4nderung%20f%C3%BCr%20unsere%20Kollegen%20in%20Konstanz%20darstellt%22%2C%20sagte%20Michael%20Hartmann%2C%20Gesch%C3%A4ftsf%C3%BChrer%20Personal%20und%20Arbeitsdirektor%20bei%20Takeda%20Deutschland.%20%22Mit%20dieser%20heutigen%20Mitteilung%20m%C3%B6chten%20wir%20unsere%20Mitarbeiter%20transparent%20informieren%20und%20fr%C3%BChzeitig%20einbeziehen%3B%20derzeit%20f%C3%BChren%20wir%20Gespr%C3%A4che%20mit%20dem%20Betriebsrat.%22%20%3C/p%3E%0A%0A%3Cp%3E%20Mit%20insgesamt%202.300%20Besch%C3%A4ftigten%20in%20Deutschland%20sowie%20zwei%20globalen%20Produktionsstandorten%20sendet%20Takeda%20ein%20starkes%20Signal%20f%C3%BCr%20seinen%20Standort%20hierzulande.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3E%C3%9Cber%20Takeda%3C/b%3E%3C/p%3E%0A%3Cp%3ETakeda%20hat%20sich%20zum%20Ziel%20gesetzt%2C%20die%20Gesundheit%20von%20Menschen%20weltweit%20zu%20verbessern%20und%20eine%20bessere%20Zukunft%20zu%20gestalten.%20Wir%20streben%20danach%2C%20transformative%20Therapien%20innerhalb%20unserer%20therapeutischen%20Kernbereiche%20wie%20gastroenterologische%20Erkrankungen%20oder%20Onkologie%20zu%20erforschen%20und%20bereitzustellen%20%E2%80%93%20dazu%20z%C3%A4hlen%20auch%20seltene%20Krankheiten%20sowie%20plasmabasierte%20Therapien%20oder%20Impfstoffe.%3Cbr%20/%3E%20Durch%20Partnerschaften%20wollen%20wir%20die%20Lebensqualit%C3%A4t%20unserer%20Patienten%20steigern%20sowie%20innovative%20Behandlungsm%C3%B6glichkeiten%20durch%20unsere%20vielf%C3%A4ltige%20Pipeline%20schaffen.%3Cbr%20/%3E%20Als%20forschungsorientiertes%20biopharmazeutisches%20Unternehmen%20mit%20Sitz%20in%20Japan%20leitet%20uns%20unser%20Engagement%20gegen%C3%BCber%20Patienten%20ebenso%20wie%20gegen%C3%BCber%20unseren%20Mitarbeitern%20sowie%20unserem%20Planeten.%3Cbr%20/%3E%20Diese%20Motivation%20treibt%20Teams%20aus%20rund%2080%20L%C3%A4ndern%20an%3B%20mehr%20Informationen%20finden%20Sie%20unter%20www.takeda.de.%3C/p%3E%0A%0A%3Cp%3EPressekontakt%3A%3C/p%3E%0A%3Cp%3ETakeda%20Pharma%20Vertrieb%20GmbH%20%26%20Co.KG%3Cbr%20/%3E%3Cbr%20/%3E%0ACorporate%20Affairs%3Cbr%20/%3E%0ADr.Friedrich%20von%20Heyl%3Cbr%20/%3E%0AMobil%3A%20%2B49%20160%204725%20490%3Cbr%20/%3E%0AE-Mail%3A%20pr%40takeda.com%3Cbr%20/%3E%3Cbr%20/%3E%0ACorporate%20Communications%3Cbr%20/%3E%0ANina%20von%20Reden%3Cbr%20/%3E%0AMobil%3A%20%2B49%20172%206331%20753%3Cbr%20/%3E%0AE-Mail%3A%20pr%40takenda.com%3C/p%3E%0A%60%60%60

%60%60%60html%0A%3Cimg%20height%3D%27540%27%20with%3D%27720%27%20src%3D%27https%3A//cache.pressmailing.net/thumbnail/story_big/624022e5-b731-41c7-8b11-be6307ad65be/brite-tm-plattform-von-xo-life-digitale-therapiebegleitung-f-r-menschen-mit-mukoviszidose%27%20srcset%3D%27https%3A//cache.pressmailing.net/thumbnail/story_big/624022e5-b731-41c7-8b11-be6307ad65be/brite-tm-plattform-von-xo-life-digitale-therapiebegleitung-f-r-menschen-mit-mukoviszidose%20710w%2C%20https%3A//cache.pressmailing.net/thumbnail/story_small/624022e5-b731-41c7-8b11-be6307ad65be/brite-tm-plattform-von-xo-life-digitale-therapiebegleitung-f-r-menschen-mit-mukoviszidose%20532w%27%20sizes%3D%27%28min-width%3A%201360px%29%20720px%2C%20%28min-width%3A%201000px%29%2054.71vw%2C%20%28min-width%3A%20780px%29%20calc%2866.5vw%20-%2072px%29%2C%20calc%28100vw%20-%2048px%29%27%20alt%3D%27brite%28TM%29-Plattform%20von%20XO%20Life%3A%20Digitale%20Therapiebegleitung%20f%C3%BCr%20Menschen%20mit%20Mukoviszidose%27%20class%3D%27single%27/%3E%0A%0A%3Cp%3EVertex%20Pharmaceuticals%2C%20ein%20amerikanisches%20Unternehmen%20der%20Pharmaindustrie%20mit%20einem%20Schwerpunkt%20auf%20schweren%20Erkrankungen%20wie%20Mukoviszidose%2C%20Beta-Thalass%C3%A4mie%20und%20Sichelzellkrankheit%2C%20hat%20eine%20Partnerschaft%20mit%20XO%20Life%20bekannt%20gegeben.%20Diese%20Kooperation%20zielt%20darauf%20ab%2C%20eine%20digitale%20Begleitl%C3%B6sung%20f%C3%BCr%20die%20Therapie%20von%20Patienten%20mit%20Mukoviszidose%20zu%20entwickeln.%20Im%20Rahmen%20dieser%20Zusammenarbeit%20wird%20ein%20neuer%20Bereich%20auf%20der%20brite%28TM%29-Plattform%20geschaffen%2C%20die%20sowohl%20als%20Webanwendung%20als%20auch%20in%20Form%20einer%20App%20verf%C3%BCgbar%20ist%20und%20sich%20an%20Personen%20richtet%2C%20die%20an%20Zystischer%20Fibrose%20%28CF%29%20leiden.%20Nach%20R%C3%BCcksprache%20mit%20ihrem%20Arzt%20k%C3%B6nnen%20Patienten%20sich%20kostenlos%20registrieren%20und%20ihre%20Therapie%20digital%20verfolgen%20sowie%20dokumentieren%20und%20dabei%20medizinisch%20fundierte%20Informationen%20abrufen.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EMukoviszidose%3A%20Eine%20h%C3%A4ufige%20genetische%20Erkrankung%20in%20Europa%3C/b%3E%3C/p%3E%0A%0A%3Cp%3EZystische%20Fibrose%20%28CF%29%2C%20besser%20bekannt%20als%20Mukoviszidose%2C%20z%C3%A4hlt%20zu%20den%20h%C3%A4ufigsten%20seltenen%20genetischen%20Erkrankungen%20in%20Europa%20und%20f%C3%BChrt%20oft%20zu%20einer%20verk%C3%BCrzten%20Lebenserwartung.%20Die%20Krankheit%20entsteht%20durch%20Mutationen%20im%20CFTR-Gene%20%2C%20was%20dazu%20f%C3%BChrt%20dass%20das%20CFTR%20Protein%20entweder%20defekt%20oder%20gar%20nicht%20vorhanden%20ist.%20Infolgedessen%20kommt%20es%20zu%20einem%20unzureichenden%20Austausch%20von%20Salz%20und%20Wasser%20zwischen%20den%20Zellen%20verschiedener%20Organe%20wie%20der%20Lunge.%20Dies%20bewirkt%20eine%20Verdickung%20des%20Schleims%20in%20den%20Atemwegen%20sowie%20anderen%20Dr%C3%BCsen%20des%20K%C3%B6rpers%20und%20beeintr%C3%A4chtigt%20deren%20Funktion%20erheblich.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EDigitale%20Unterst%C3%BCtzung%20f%C3%BCr%20Patienten%20mit%20Mukoviszidose%3C/b%3E%3C/p%3E%0A%0A%3Cp%3EDer%20Therapiebereich%20innerhalb%20der%20brite%28TM%29-Plattform%20bietet%20umfassende%20medizinisch%20gepr%C3%BCfte%20Inhalte%20an%20%E2%80%93%20darunter%20Anleitungen%20zur%20Anwendung%20sowie%20Funktionen%20wie%20Erinnerungen%20zur%20Medikamenteneinnahme%20oder%20Protokollierung%20des%20Gesundheitszustands.%20Diese%20Plattform%20kann%20%C3%BCber%20das%20Internet%20oder%20via%20App%20auf%20iOS-und%20Android-Ger%C3%A4ten%20genutzt%20werden.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3EDie%20brite%28TM%29-Plattform%3A%20Ein%20transparenter%20Ansatz%20zur%20Therapie%C3%BCberwachung%3C/b%3E%3C/p%3E%0A%0A%3Cp%3E%22Es%20ist%20entscheidend%20f%C3%BCr%20seltene%20Krankheiten%20wie%20diese%20einen%20kontinuierlichen%20%C3%9Cberblick%20%C3%BCber%20den%20Therapiefortschritt%20zu%20haben%22%2C%20erkl%C3%A4rt%20Dr.%20Friderike%20Bruchmann%2C%20Mitgr%C3%BCnderin%20%26%20CEO%20von%20XO%20Life.%20%22Durch%20Daten%20aus%20dem%20Alltag%20k%C3%B6nnen%20wir%20wertvolle%20Einblicke%20gewinnen.%22%20Die%20brite%28TM%29-Plattform%20stellt%20relevante%20Informationen%20klar%20dar%20und%20f%C3%B6rdert%20so%20die%20Transparenz%20unter%20allen%20Beteiligten%20im%20Behandlungsprozess%3B%20sie%20ersetzt%20jedoch%20keine%20%C3%A4rztliche%20Beratung%20sondern%20erg%C3%A4nzt%20diese%20um%20allgemein%20verst%C3%A4ndliche%20Informationen%20sowie%20digitale%20Hilfestellungen%20bei%20der%20Therapie%C3%BCberwachung.%3C/p%3E%0A%0A%3Cp%3E%3Cb%3E%C3%9Cber%20XO%20Life%3C/b%3E%3C/p%3E%0A%20%0A%3Cp%3EXO%20Life%20hat%20eine%20innovative%20Meta-Plattform%20entwickelt%20%E2%80%93%20die%20brite%28TM%29-Plattform%20%E2%80%93%20welche%20Patienten%20w%C3%A4hrend%20ihrer%20Behandlung%20digital%20unterst%C3%BCtzt%20indem%20sie%20ihnen%20gepr%C3%BCfte%20medizinische%20Inhalte%20bereitstellt%3B%20dar%C3%BCber%20hinaus%20k%C3%B6nnen%20Nutzer%20ihren%20Gesundheitsverlauf%20dokumentieren%20sowie%20personalisierte%20Einblicke%20erhalten%20oder%20sich%20untereinander%20austauschen.%3Cbr%20/%3EHersteller%20haben%20zudem%20die%20M%C3%B6glichkeit%20ihre%20eigenen%20Produktbereiche%20innerhalb%20dieser%20Plattform%20anzubieten%20inklusive%20individueller%20Branding-M%C3%B6glichkeiten.%3Cbr%20/%3EDurch%20ma%C3%9Fgeschneiderte%20Informationen%20tragen%20Hersteller%20aktiv%20zum%20Erfolg%20ihrer%20Therapien%20bei.%3C/p%3E%0A%20%0A%3Cp%3EXO%20Life%20gilt%20als%20Vorreiter%20im%20Bereich%20Digital%20Health%20in%20Deutschland%20und%20Europa%3B%20das%20Unternehmen%20kooperiert%20sowohl%20mit%20globalen%20Marktf%C3%BChrern%20als%20auch%20mittelst%C3%A4ndischen%20Pharmaunternehmen%20aus%20Deutschland.%3Cbr%20/%3EDie%20brite%28TM%29-Plattform%20wird%20mittlerweile%20europaweit%20angeboten.%3C/p%3E%0A%20%0A%3Cp%3EWebsite%3A%20www.xo-life.com%3C/p%3E%0A%20%0A%3Cp%3ELinkedin%3A%20https%3A//www.linkedin.com/company/xo-life%3C/p%3E%0A%20%0A%3Cp%3EYouTube%3A%20https%3A//www.youtube.com/%40xo-life/featured%3C/p%3E%0A%20%0A%3Cp%3E%3Cb%3EQuellen%3A%3C/b%3E%3C/p%3E%0A%20%0A%3Cul%3E%0A%3Cli%3ECfsource.de%20-%20Ursachen%20der%20Mukoviszidose%20%5BZugriff%20Juni2023%5D%3C/li%3E%0A%3Cli%3ECfsource.de%20-%20Symptome%20bei%20Mukoviszidos%20%5BZugriff%20Juni2023%5D%3C/li%3E%0A%20%3C/ul%3E%0A%0A%0A%20%3Ch2%3EPressekontakt%3A%3C/h2%3E%0A%0A%20%3Caddress%20%3E%0AXO%20Life%20GmbH%3Cbr%20/%3E%0ADr.med.Lisa%20M.K%C3%B6hler%3Cbr%20/%3E%0ALeiterin%20Medizinischer%20Angelegenheiten%20%26%20Pharmakovigilanz%3Cbr%20/%3E%0AAgnes-Pockels-Bogen1%3Cbr%20/%3E%0A80992%20M%C3%BCnchen%3Cbr%20/%3E%0AE-Mail%3A%3Ca%20href%3D%22mailto%3Apr%40xo-life.com%22%3E%20pr%40xo-life.com%20%3C/a%20%3E%0A%20%3C/address%20%3E%0A%0A%60%60%60